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In 2010, there were 2839 women and 13 men diagnosed with breast cancer in Norway, which 
was equivalent to an increase of almost 50% since 1956. The risk of developing breast cancer 
increases with age, and will affect one in ten women during their lifetime. Despite a 
substantial increase in the number of early-stage breast cancers detected due to screening-
programs, there is still a need for new and improved prognostic tools and therapies for a 
disease with such distinctive gene expression signature and cellular composition, essential for 
both the biological and clinical features of the disease. 
The deregulation of single-stranded RNA molecules called microRNAs (19-23 nt long) is 
associated to development and progression of several cancers, including in breast cancer. This 
has opened up the prospect of a potential role both as biomarkers, markers of cancer 
progression and prognosis and therapeutic targets. miRNAs regulate the cell‟s gene activity 
and protein synthesis, and their function can be both cancer-repressing and cancer-
stimulating. It has been shown that miRNAs regulates the expression of the protein-coding 
components of many cell signaling pathways, however the complete picture of  how these key 
cell signaling systems are regulated by miRNAs and regulate miRNA biogenesis remains to 
be described.   
The extracellular signal-regulated kinase 3 (ERK 3) and -kinase 4 (ERK 4) are members of 
the atypical subgroup of MAP kinases. There is little knowledge about the upstream 
regulation of ERK3/4, and also their downstream targets. To this day, MAPK-activated 
protein kinase 5 (MK5) is the only known substrate of ERK3/4. It is believed that ERK3 is 
involved in cell differentiation and regulation of the cell cycle. The expression of ERK3 is up-
regulated in various cancers, and ERK3 may play an important role in migration and invasive 
growth of cancer cells. However, the precise molecular mechanism of ERK3, ERK4 and MK5 
in cancer and cancer-related signaling pathways remains to be unraveled. 
In this thesis we aimed to see if we could detect a microRNA that targets and regulates ERK3, 
ERK 4 or MK5, either post-transcriptionally or at the translational level. By comparing the 
results from different target expression-experiments we sought to find correlations between 
the expressions of ERK3/4 or MK5 mRNA or protein and the pertaining expression of 
putative miRNAs with potential binding sites in the 3‟UTR of these atypical kinases. Our 
experiments revealed the presence of ERK3 and MK5 protein in all breast cancer cell lines 
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1.1  Breast cancer 
Breast cancer is a type of cancer originating from breast tissue and is regarded as a collection 
of breast diseases with different histopathology, genetics and genomic variations associated 
with various clinical outcomes (1). Different factors play a part in developing breast cancer 
such as lifestyle (diet, exercise and alcohol consumption), and about 5% of the cases are 
hereditary (2). The risk of developing breast cancer increases with age and about 80% of the 
diagnosed cases are over the age of 50 (3). Breast cancer affects mostly women and in 2010, 
2839 women and 13 men were diagnosed with breast cancer in Norway, an increase of almost 
50% since 1956. The increase in breast cancer diagnoses is partly caused by earlier detection 
in women participating in the organized screening program, recommended by the Norwegian 
health government and the WHO (2, 4). This program is voluntary for women between the 
ages of 50-69 years old, and is meant to detect breast cancer at an earlier stage and by such 
probably increase the overall survival. Today, about 90% of the diagnosed women are still 
alive after 5 years. The Screening program started in 1996, and went nationwide in 2005. The 
aim is to reduce mortality of breast cancer by early detection. However, several studies have 
claimed that despite a substantial increase in the number of early-stage breast cancers 
detected, screening is having, at best, only a small effect on the rate of death from breast 
cancer (5, 6). 
 
1.2  Classification of breast cancer 
 
Every tumor has a distinctive gene expression signature, and its cellular composition is 
essential for both the biological and clinical features of the disease (7). Different clinical and 
pathological factors are used to categorize patients with breast cancer in order to assess 
prognosis and determine the appropriate therapy. These include patient age, axillary lymph 
node status, tumor size, histological grade and lymphovascular invasion, hormone receptor 
status, and HER2 status (8). Breast cancer is divided into different stages to determine the 
course of treatment. TNM-classification describes primary tumor (T), clinical lymph node 
status (N) and histological lymph node status (pN), and metastasis (M) (9). Tumors are 
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classified by gene expression patterns, and there are five common subtypes of ductal 
carcinoma. Mainly, the distinction between these subtypes is tumors described as estrogen 
receptor (ER)-positive, called luminal A and luminal B, and tumors that are ER-negative, 
called basal-like, ERBB2+ and normal breast tissue-like subtype (1, 7, 10, 11). 
Basal (and/or myoepithelial) cells and luminal epithelial cells are two distinct types of 
epithelial cells found in the human mammary gland (11). The luminal subtypes make up the 
hormone receptor– expressing breast cancers, and around 60-70% of invasive breast cancers 
are classified as “luminal group” (8). They have expression patterns resembling the luminal 
epithelial component of the breast, which include expression of luminal cytokeratins 8/18, ER 
and genes associated with active ER pathway such as LIV1 and CCND1 (also known as 
cyclin D1) (12). Expression of ER is essential for proliferation of luminal subtypes, and both 
ER and the transcription factors FOXA1 and GATA3 are crucial for the lineage-specific 
differentiation path in breast epithelial cells. The epithelial to mesenchymal transition (EMT) 
is inhibited by FOXA1, and so is cell growth. Expression of this transcription factor is 
associated with luminal A subtype breast cancers, and also correlates with ER expression and 
good prognosis (13, 14). Depending on the level of expression of other genes belonging to the 
proliferation cluster and HER-2/neu, the luminal-group is further divided into luminal A and 
luminal B (15). Luminal B tends to overexpress HER2, and about 30% are HER2-positive 
(whereas the luminal A group is HER2-negative). The two subtypes are also distinguished by 
assessing the proliferative rate (determined by Ki67 expression) and the histological grade, 
both of which are higher in the luminal B group (8).  
The basal-like subtype is responsible for about 15-20% of invasive breast cancers. It is 
associated with aggressive behavior and poor prognosis and about 70-80% are triple-negative 
phenotypes (typically does not express hormone receptors or HER-2). Basal-like breast 
tumors consistently express genes usually expressed in normal basal/myoepithelial cells of the 
breast (16-18), including basal cytokeratins 5/6, 14 and 17, p-cadherin and caveolin 1 (10, 19-
21). Many of the gene products, all hallmarks of cancer, are implicated in cellular 
proliferation, suppression of apoptosis, cell migration and/or invasion. Basal-like tumors also 
under-express genes characteristic of luminal epithelial cells of the normal mammary gland, 
and also genes located in the HER2 amplicon on 17q21 (8, 15). Aggressive features such as 
TP53 mutations and being grade III are more likely in this subtype of breast cancer than for 
the luminal A group (12). 
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Both the morphological features and the gene expression profile of basal-like breast cancers 
are remarkably similar to those of tumors arising in breast cancer 1, early onset gene (BRCA1) 
mutation carriers (22-26). BRCA1 tumors are usually characterized as high-grade, highly 
proliferating, estrogen receptor-negative and HER2-negative. They generally express basal 
markers such as basal keratins, P-cadherin and epidermal growth factor receptor (EGFR), and 
often carry p53 mutations (27-30). BRCA1, which functions in cell cycle checkpoint 
responses and plays an important role in DNA double-strand break repair, contributing to the 
maintenance of DNA stability, may therefore have an impaired pathway in many basal-like 
breast cancers (12, 31). 
HER-2-overexpressing tumors represent about 10-15% of invasive breast cancers (8), and 
express high levels of genes located in the ERBB2 amplicon on 17q21. Gene products include 
HER-2 and growth factor receptor-bound protein 7 (GRB7), the transcription factor GATA4, 
and a high level of nuclear factor (NF)-κB activation. These tumors lack expression of ER/PR 
and GATA3 (15). As with basal-like tumors, the HER2-overexpressed tumor‟s poor prognosis 
seems to be derived from a higher risk of early relapse among those without complete 
eradication of tumor cells (10, 12). As with basal-like tumors, the HER2-overexpressed 
tumors are more likely to have a high proportion of TP53 mutations, significantly more likely 
to be grade 3 and involve axillary lymph nodes than luminal A tumors (8, 12).  
The normal breast tissue-like group is still poorly categorized (32), but resemble normal 
breast tissue samples and show high expression of many genes expressed by adipose tissue 
and other non-epithelial cell types, and low expression of genes characteristic of luminal 
epithelial genes (7, 10, 11, 15). It has been suggested that this subgroup may be a mere artifact 
of disproportionally high content of normal tissue contamination.  
In addition to the luminal-, basal- and HER2-subtypes, at least three other molecular groups 
of ER-negative cancers have been described. The „molecular apocrine‟ group of tumors has 
been claimed by some to be similar to the HER2-positive/ER-negative subtype and appears to 
have activation of the androgen receptor signaling. The „interferon‟ subtype is characterized 
by high expression of interferon regulated-genes, including STAT1. And finally, the „claudin-
low‟ subgroup comprises tumors that are characterized by a low (or absent) expression of 
luminal differentiation markers, high expression of epithelial-to-mesenchymal transition 
markers, immune response genes and cancer stem cell-like features (33). Clinical and 
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biological significance of tumors pertaining to these newly described classes remains to be 
determined (32). 
 
1.3  Breast cancer cell lines 
 
There is a necessity for the use of different model systems in breast cancer research to 
investigate the complex pathobiology of breast cancer, and to screen for and characterize new 
therapeutics. Breast cancer cell lines are widely employed, and have contributed a 
considerable part of our knowledge on breast carcinomas, such as insight into the deregulation 
of proliferation, apoptosis and migration during progression of breast cancer (1, 34). In 
applying breast cancer cell lines under well-defined experimental conditions, the results will 
generally be reproducible and quantifiable. Other advantages such as the cells being amenable 
to genetic manipulation and easily propagated are some of the reasons why such a model 
system is the principal in breast cancer research (1). Studies using rodent cells have also 
provided current understandings of how cell transformation occurs in human tissues. Recent 
evidence show that human epithelial cells require more genetic alterations to transform than 
their murine counterparts, suggesting that human cells in research are more relevant to human 
disease (35, 36). 
Through gene expression profiles, breast cancer cell lines can be divided into three groups; 
luminal, basal-A and basal-B. The luminal subtype comprises ER-positive cell lines and is 
characterized by the expression of ERα-regulated genes, as well as genes associated with 
luminal epithelial differentiation like GATA3 and FOXA1 (37). Cell lines in the basal-A 
subgroup are ER-negative, express basal epithelial gene markers and some luminal epithelial 
markers, as well as a marker of cancer stem cells (PROM1) (37, 38). The basal-A subtype is 
also associated with the breast cancer 1, early onset gene signatures (BRCA1), and the 
erythroblast transformation specific pathway (ETS-pathway) (37). Similar to the basal-A 
subgroup, the basal-B subgroup consist of ER-negative cell lines. The basal-B subgroup 
generally express basal epithelial gene markers (like Moesin, ETS1, CAV1 and EGFR) (37, 
39, 40), and show features of aggressive tumors (plasminogen activator and TGFB1) (41, 42), 
invasiveness (epithelial mesenchymal transition) (43), and markers for normal breast and 
breast cancer stem cells (44). A subset of this group also lacks the expression of the basal 
cytokeratin markers KRT5 and KRT17 (37).  
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Tumor subtypes show close similarities to breast cancer cells when comparing them to the 
tumor‟s gene expression patterns. Where the luminal-A or luminal-B tumors resemble the 
luminal cell lines, most basal-A cell lines resemble basal-like tumors, and most basal-B cell 
lines resemble either basal-like or ERBB2 tumors (31). A reverse comparison of breast 
tumors to the cell line subtypes show that the ERBB2 subtype tumors show conformity to 
either luminal or basal-A cell lines (37). The fact that the cell lines mirror many, but not all, of 
the genomic and biological properties of primary tumors, may be due to the absence of 
normal epithelial or stromal cells affecting the genetic profile of breast cancer cell lines. Lack 
of stromal or physiological interactions or signaling in cell culture may also account for some 
of the differences. Culture conditions selecting for subpopulations of breast tumors may be a 
cause for the differences between genome aberration patterns for the basal-like and luminal 
clusters in the cell lines, and these subtypes in primary tumors. Hence cell cultures show a 
smaller variation in gene expression profiles than breast tumor subtypes. Yet, cell lines still 
largely reflect the genomic heterogeneity and the recurrent genome copy number 
abnormalities found in primary tumors (45). 
 
1.4  Protein kinases and phosphatases 
 
Protein kinases and phosphatases play important roles in regulating and coordinating aspects 
of metabolism, gene expression, cell growth, motility, differentiation and division in normal 
cells (46). The protein kinases are important enzymes in cellular signaling, and carry out their 
action by covalently attaching phosphate to side chains of the amino acids tyrosine, serine and 
threonine of specific proteins. When enzymatic proteins are phosphorylated, this will control 
their activity and interactions with other molecules, their location in the cell and also their 
susceptibility for degradation proteases. These are proteins that remove the previously 
transferred phosphates from the protein-substrates (47). 
An extracellular signal can be transduced and amplified in cells through the protein kinase 
cascades. Receptors activate tyrosine phosphorylations, and the protein kinases tightly 
regulate the intracellular signaling pathways (48). A deregulation of these processes by the 
occurrence of mutant alleles disrupting the signaling might lead to malignant changes in cell 
differentiation, division, motility and apoptosis. The protein kinases can be subdivided into 
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three categories based upon their catalytic specificity: those specific for tyrosine, those 
specific for serine/threonine and those specific for both tyrosine and serine/threonine (49, 50). 
 
1.5  Protein tyrosine kinases 
 
There are two classes of protein tyrosine kinases (PTKs) present in cells: the transmembrane 
receptor PTKs and the non-receptor PTKs. The non-receptor PTKs (NRTKs) are cytoplasmic 
proteins triggered by the receptor tyrosine kinases (RTKs) (51). Receptor protein tyrosine 
kinases are transmembrane glycoproteins that after activation by ligand-bidning, induces 
dimerization and activation of the receptor tyrosine kinases, which autophosphorylate and 
transfers the signals to the cytoplasm (48).   
Cytoplasmic signaling pathways that are activated by PTKs include the Ras/Raf mitogen-
activated protein kinase pathway, the phosphoinositol 3-kinase/Akt pathway, the signal 
transducer and activator of transcription 3- pathway and the protein kinase C -pathway. 
Signals are transferred from membrane receptors into the nucleus by intracellular mediators in 
these pathways, where they culminate and cause altered DNA synthesis and cell division as 
well as effects on different biological processes such as cell growth, migration, differentiation, 
and apoptosis (50).  
The development of cancer may happen through several mechanisms in cells. Many factors 
contribute to the activation of cell cycle and other processes involved in cancer, such as 
mutations in the tumor suppressor p53, overexpression of different growth factors (like VEGF 
or TGF-α) or growth factor receptors (like PDGFR or EGFR), or the deregulation of kinases 
(like ABL) and activation of oncogenes (like the Ras/Raf pathway) (52). 
 
1.6  Mitogen-activated protein kinases 
 
Mitogen-activated protein kinases (MAPKs) convert extracellular stimuli into a wide range of 
cellular responses. They are protein Serine/Threonine kinases, and MAPK pathways regulate 
gene expression, mitosis, metabolism, motility, survival, apoptosis, and differentiation (53). 
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The extracellular signal-regulated kinases 1/2 (ERK1/2), p38 MAPK-isoforms, c-Jun amino 
(N)-terminal kinases 1/2/3 (JNK1/2/3) and ERK5 all belong to the conventional MAPKs (54, 
55). Atypical MAPKs comprise ERK3/4, ERK7, and Nemo-like kinases (NLK), and do not 
share many characteristics of conventional MAPKs (56, 57). 
The MAP-kinase cascade consists of sequentially acting kinases: a MAPK, a MAPK kinase 
(MAP2K), and a MAPKK kinase (MAP3K) (see Figure 1). Activation of the MAP3Ks is often 
through phosphorylation or in response to extracellular stimuli through interaction with a 
small GTP-binding protein of the Ras/Rho family. The activation of MAP3K leads to a 
MAP2K being phosphorylated and activated, which then in turn phosphorylates the tyrosine 
and threonine residues on a MAPK, activating it. Phosphorylation of these Thr/Tyr-residues is 
essential for enzymatic activities(58) . 
MAPKs can phosphorylate several substrates, including the protein kinases called MAPK 
activated protein kinases (MAPKAPKs or MKs), which comprises of the p90 ribosomal S6 
kinases (RSKs), mitogen- and stress- activated kinases (MSKs), MAPK-interacting kinases 
(MNKs), MAPK-activated protein kinase 2/3 (MK2/3) and MK5. These kinases represent 






Figure 1. MAPK signaling cascade leads to activation of the MAPKAPKs. This figure is showing a part of 
the different MAPK pathways, which is activated through stimulation from various cellular stress signals, 
mitogens and cytokines. Activation of the pathway leads to phosphorylation and activation of subgroups in the 
cascade, including the MAPK-activated kinase, MK5. The dotted line represents the fact that substrate regulation 
of MK5 by p38 α/β is not yet fully demonstrated. This figure is modified from Cargnello M. and Roux P. 2011 




1.7  Atypical MAP kinases 
 
Atypical MAP kinases are divided into ERK3 (MAPK6), ERK4 (MAPK4), nemo-like kinase 
(NLK) and ERK7 (MAPK15). One distinctive feature that sets the conventional MAP kinases 
apart from the atypical MAP kinases ERK3 and ERK 4 is that tyrosine in the activation loop 
(Thr-Xaa-Tyr), which is the site of activating phosphorylation by the MAP2K family 
members, is replaced with a glutamic acid residue.  The activation loop in ERK3and ERK4 
therefore contains a single phospho-acceptor site (Ser–Glu–Gly, or SEG). Subdomain VIII of 
the kinase domain also contains an altered sequence in ERK3 and ERK4. As the only known 
kinases in the human genome, that domain contains the sequence Ser–Pro–Arg instead of 
Ala–Pro–Glu (57).  
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ERK3 is found to be a highly unstable protein, degraded by the proteasome-enzyme, and is 
found in both the cytoplasmic and nuclear compartments in exponentially proliferating cells. 
Unlike ERK3, ERK4 is a stable protein and is predominantly localized in the cytoplasm. They 
have both been implicated in cell regulation and cancer metastasis and migration (60, 61). 
Binding of ERK3/4 to MK5 is accompanied by phosphorylation and activation of this 
MAPK-activated protein kinase (57, 62). ERK3 has also been seen as a physiological target 
for MK5 (63). 
 
Figure 2. Schematic representation of the structure of the atypical MAP kinases ERK3 and ERK4. MAP 
kinases consists of a kinase domain (in yellow) flanked with an N- terminal, and a C-terminal with different 
lengths.  C34 is a conserved region in ERK3/4 (56, 57). 
 
MK5, a 54 kD protein part of the MAPK-activated protein kinases (the MAPKAPKs or MKs) 
is activated through phosphorylation of its threonine 182 (T182) by JNK, ERK2 and p38 
MAPKs (64). In cells, MK5 is found both in the nucleus and the cytoplasm,  but mainly in the 
nucleus of resting cells (65). With MK5 being a part of the atypical MAPK cascade, the 
structure contains a region for binding ERK3 and ERK4 in the C-terminal. This is an 
extension from the NLS of a 100 amino acids, which differs from the conventional 
MAPKAPKs MK2 and MK3. The catalytic domain of MK5 is found in the N-terminal 
domain (see Figure 3) (66, 67). There is also a docking motif for the p38 MAPK, and a p38-
isoform may activate MK5 in vivo (68). The nuclear export sequence (NES) and the nuclear 





Figure 3. Schematic representation of the structure of the MAPK-activated protein kinase MK5. NES: 
nuclear export signal, NLS: nuclear localization signal, D: D domain/MAPK docking site, ERK3/4: docking site 
for ERK3/4 (56, 69). 
 
1.8  Non-protein coding RNAs 
 
For many years it was generally assumed that most genetic information was transacted by 
proteins, however, it is now clear that the majority of the genomes of mammals and other 
complex organisms is in fact transcribed into non-protein coding RNAs (ncRNAs). Non-
protein coding RNAs do not encode proteins, but function directly at the level of the RNA in 
cells, and the importance of this diverse class of molecules is widely recognized (70-73). 
Although only 2% of the mammalian genome encodes mRNAs, the vast majority is 
transcribed, largely as long and short ncRNAs (74-76). Their functions include DNA 
replication, chromosome maintenance, regulation of transcription, regulation of translation, 
RNA processing (including RNA cleavage, -re-ligation, -modification and –editing), 
regulation of mRNA stability and regulation of stability and translocation of proteins (73, 77-
81). 
Non-protein coding RNAs include both “housekeeping” RNAs, such as transfer RNAs 
(tRNAs), ribosomal RNAs (rRNAs), small nuclear RNAs (snRNAs) and small nucleolar 
RNAs (snoRNAs), as well as regulatory ncRNAs. Regulatory ncRNAs are generally grouped 





1.9  Small regulatory RNAs 
 
At least three classes of small RNAs are encoded in our genome, based on their biogenesis 
mechanism and the type of Ago protein that they are associated with: microRNAs (miRNAs), 
endogenous small interfering RNAs (endo-siRNAs or esiRNAs) and Piwi-interacting RNAs 
(piRNAs).  
miRNA is by far the most studied and best understood among the three classes.  miRNAs are 
endogenous, evolutionary conserved, single-stranded RNA molecules (18–25 nt) that are 
involved in specific regulation of gene expression in eukaryotes. The first miRNA (called lin-
4) was discovered by Ambros and coworkers in 1993, from Caenorhabditis elegans, however 
it took seven years before the second miRNA was discovered (let-7). This observation 
triggered the construction and characterization of several large-scale cDNA libraries enriched 
for small RNAs and led to the identification of thousands of miRNAs in organisms as diverse 
as viruses, plants, worms, and mammals (85-89). The number of miRNAs in the human 
genome is currently estimated to be 1600 precursor- and 2042 mature miRNAs (90). 
 
miRNAs are generated from local hairpin structures by two RNase III proteins; Drosha and 
Dicer. This generates mature miRNAs of 22 nt that are subsequently bound by Ago-
subfamily proteins. miRNAs generally target mRNAs and function as post-transcriptional 
regulators. It is predicted that the miRNA genes comprise 1–2% of the human genome and 
that miRNAs control the activity of about 50% of all protein-coding genes (91, 92).   
 
siRNAs differ from miRNAs in that they are derived from long double-stranded RNAs 
(dsRNAs) and are dependent only on Dicer and not on Drosha (83, 93, 94). siRNAs are also 
considered to be generally exogenous RNA molecules that are taken up by cells, or enters via 
vectors like viruses. They are also slightly shorter ( 21 nt) than miRNAs and, at least in 
animals, siRNA typically binds with complete complementarity to its mRNA target and 
regulates gene expression by inducing mRNA cleavage (95). 
piRNAs are the longest of the three classes (24–31 nt in length), and are associated with Piwi-
subfamily proteins. Intriguingly, the biogenesis of piRNAs does not depend on Dicer (96). 
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piRNAs are highly abundant in germ cells and have been implicated in transposon silencing 
through heterochromatin formation or RNA destabilization (97). 
 
1.10 MicroRNA Biogenesis 
 
The biogenesis of a miRNA starts in the cell nucleus. The pri-miRNA can be several 
hundreds or thousands of nucleotides (nt), and are usually transcribed by RNA polymerase II 
(98, 99), or in some cases by RNA polymerase III (100). The primary miRNA transcript is 
characterized by a stem loop structure, and is further processed in the nucleus by an RNase III 
endonuclease, Drosha, which cleaves both strands of the stem at sites near the base of the 
stem loop and releases the pre-miRNA. Drosha is part of a large protein complex called the 
microprocessor, containing the DiGeorge syndrome component region gene 8 protein 
(DGCR8). Drosha serves as the catalytic unit, while DGCR8 recognizes the pri-miRNA and 
stabilizes it‟s interaction with Drosha (98, 101).  The resulting pre-miRNAs will be 60- to 100 
nt long hairpin structures with a 5‟phosphate and   2-nt 3‟ overhang at the base (98). 
After being processed in the nucleus, this pre-miRNA is recognized by Ran-GTP and the 
export receptor Exportin-5 transporter-complex, and actively exported into the cytoplasm. 
The nuclear cut by Drosha defines one end of the mature miRNA. The other end is processed 
in the cytoplasm by the enzyme Dicer (98). Dicer is a multidomain protein that consists of a 
double stranded binding domain (dsRBD), a RNAhelicase/ATPase domain, a PAZ 
(Piwi/Argonaute/Zwille) domain, two neighbouring RNase III-like domains (RIIIDs) and the 
DUF283 domain. The dsRBDs and RIIDs gives Dicer a preference for processing double 
stranded RNA substrates with 3‟overhangs, while the PAZ domain recognizes the 3‟-
protruding ends of the substrates and cleaves the double stranded region two helical turns 
away from the stem-loop.  The result is a miRNA duplex (about 22 nt long), which includes 
the mature miRNA guide strand and the complementary passenger strand (miR-3p/miR-5p) 
(98, 102). 
The transactivating response RNA-binding protein (TRBP) and protein activator of protein 
kinase R (PACT) facilitate Dicer-mediated cleavage of the pre-miRNA by binding and 
stabilizing Dicer (103, 104). They are also important regulatory factors that contribute to both 
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substrate and cleavage specificity, and the selection of which miRNA strand that is transferred 
to the RNA-induced silencing complex (RISC) or miRgonaute (98, 105). Indeed the PACT-
TRBP–Dicer complex provides a platform for RISC assembly and aids recruitment of 
Argonaute proteins (in humans, usually Ago2), the catalytic enzyme of RISC required for 
miRNA processing (103, 104, 106). 
 
The Ago proteins are central for RISC function and contain two conserved RNA binding 
domains: a PAZ domain that bind the single stranded 3‟ end of the mature miRNA and a 
PIWI domain that interact with the 5‟ end of the guide strand. These domains bind the mature 
miRNA and position it for interaction with a target mRNA. Some Ago proteins (for example 
Ago2), cleave target transcripts directly while others recruit additional proteins to achieve 
translational repression (107). RISC with incorporated miRNA is generally referred to as 
"miRISC”, and this complex can now, dependent on the sequence complementarity between 
the miRNA and its mRNA target, regulate the expression of target mRNAs. Binding to target 
mRNAs usually happens through partial complementarity and lead to a coupled mRNA 
degradation and inhibition of translation (108, 109). 
Mirtrons are relatively recently characterized cellular RNA interference (RNAi) effectors 
produced via a non-classical miRNA pathway. They are generated by using a splicing and 
intron lariat-debranching enzyme machinery that bypass Drosha cleavage. The dependence on 
the remainder of the RNAi pathway is variable, however the mirtron pathway generally 
converges with the miRNA pathway during export of hairpin structures from the nucleus to 





Figure 4. The miRNA biogenesis pathway. This recognized maturation pathway of mammalian miRNAs starts 
in the nucleus with RNA polymerase II cleaving the primary transcript (pri-miRNA), which is further processed 
by the microprocessor complex Drosha-DGCR8.  This generates the pre-miRNA which is exported to the 
cytoplasm by Exportin-5-Ran-GTP.  The RNase Dicer-complex cleaves the miRNA hairpin structure into its 
mature length of 19-25 nt. The duplex is unwound, and the guide strand  is incorporated into RISC while the 
passenger strand usually is degraded. The miRISC complex can then be guided to its target, and achieve gene 




1.11 MicroRNA genes 
 
miRNAs are present in all plants and animals that have been studied so far, suggesting an 
early origin of these RNA-molecules (78). Many miRNAs may be clade- or organism-
specific, though the number of miRNAs in a genome is still subject for discussion (114). 
Although the number of of miRNAs in the human genome is still in some flux, it is currently 
estimated to be 1872 precursor- and 2579 mature miRNAs (115) 
Approximately 30% of miRNA genes can be found in intergenic regions (between genes), 
distant from earlier annotated genes (78). These miRNAs have their own promoter region 
(116, 117), and their expression is thought to be regulated by the same molecular mechanisms 
that control the expression of protein-coding genes. 
The majority of miRNA genes are located in defined transcription units, predominantly 
located inside introns and usually oriented on the same DNA strand of the host gene (118). 
This involves both protein-coding genes and non-protein coding genes. Most intragenic 
(inside genes) miRNA genes are thought not to be transcribed by their own promoters, but to 
have the same orientation and promoters as their host genes. This might imply that at least for 
the protein-coding genes, they serve as hosts for co-transcribed miRNAs, giving a coordinated 
expression of miRNAs and proteins and a  potential co-regulation of host mRNA splicing and 
miRNA biogenesis (78, 119). 
Exon-derived miRNAs are quite rare and are generally encoded by exons of long non-protein-
coding transcripts, also called mRNA-like noncoding RNAs (mlncRNAs) (120). 
Introns that comprise the exact sequence of the pre-miRNA with splice sites on either side are 
called mirtrons. These are spliced out of the host transcripts and form secondary structures 
resembling those of pre-miRNAs. In this manner the debranched introns enter the miRNA-
processing pathway without Drosha-mediated cleavage (121). 
Approximately 50% of mammalian miRNA loci are found in close proximity to other 
miRNAs. MicroRNAs that are clustered close together in the same genome may be expressed 
from one primary transcript. Such polycistronic transcripts are several kilobases long in 
mammals, and represent over 40% of human miRNAs (114). MicroRNAs within a cluster are 
often related to each other (120), and have highly similar expression profiles. One possibility 
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for this is that the transcription is driven by a single promoter. Yet another possibility might 
be that each miRNA is transcribed by their own promoter from the ~70 nt precursor 
transcript, but that the transcription is controlled by a common enhancer (122). Most 
mammalian miRNA genes have multiple isoforms and this is probably caused by gene 
duplications. The largest families of human miRNA isoforms include let-7 (14 members) and 
miR-30 (6 members). miRNA isoforms are divided in two types: (1) When the mature 
miRNAs are of nearly identical sequences (usually differing by 1–3 nt),  the families are 
designated with a letter (e.g. let-7b and let-7c). (2) When miRNA genes produce identical 
mature miRNA from different precursor genes, the families are designated with a number 
implying that each gene produces the identical mature miRNA (e.g. let-7a-1 and let-7a-2). In 
the latter case each isoform is usually located on different chromosomes. The isoforms 
(isomirs) often have identical sequences at nucleotide positions 2–7 (called the seed region) 
relative to the 5' end of the miRNA. Because these nucleotides are critical in base pairing with 
the target mRNA, the isomirs are thought to act redundantly. Still, the 3' sequences of 
miRNAs also contribute to target binding and because the expression patterns of these sister 
miRNAs are often different from each other, members of the same seed family might have 
distinct roles in vivo (123). 
 
1.12 The mechanism of miRNA mediated gene silencing 
 
There is an ongoing search for the exact mechanism by which miRISC regulates translation of 
its target genes (95, 124-126). In animals the theory was originally that miRNAs repressed 
translation, but had no influence on the level of their mRNA targets. In plants on the other 
hand, miRNAs were thought to promote mRNA cleavage and degradation because of their 
perfect miRNA-mRNA complementarity, excluding translational repression which is thought 
to stem from mismatches and bulges. However, it has now become more clear that also 
miRNA-mediated mRNA degradation occurs in animals, initiated by deadenylation and 
decapping, followed by exonucleolytic digestion of the mRNA (95, 127). Translational 
repression has further been proposed to occur in four different ways: repression at the 
translation initiation step (128-131), cotranslational peptide degradation (132), increased 
premature termination (ribosomal drop-off) (133) and impaired elongation (125). In any case 
17 
 
it has become clear that miRNAs cause mRNA degradation or translational repression in both 
plants and animals, but there are still insecurities as to whether silencing occurs with 
translational repression at the initiation step or with degradation of mRNA targets at following 
stages (95). 
A paper published in 2010 by Bartel and colleagues concluded that the main reason for 
reduction in protein expression seems to be miRNA-mediated destabilization of mRNA 
targets. By using ribosome profiling to compare the protein production and mRNA levels, 
they discovered that around 84% of the lowered amount of protein was due destabilization of 
target mRNAs. Furthermore, the fraction of mRNA not degraded was also translated less 
efficiently (134).  
In the first step of miRNA mediated gene silencing process, the RNA-induced silencing 
complex (RISC) recruits one strand from the miRNA/miRNA* duplex by loading it onto an 
Ago protein at the core of the miRISC (135). This miRNA-strand, termed the guide-strand, 
can now recognize the sequence of its RNA target (136). The mechanism for gene regulation 
by miRISC seems to be influenced by the degree of complementarity between the guide-
strand and its target mRNA (95). Several computational and biochemical studies indicate that 
the specificity of target recognition by miRNAs are dependent on nucleotides 2 – 8 of the 
guide strand, also known as the „seed‟ region. At the 5‟ end of the guide strand, nucleotides 2 
– 6 are exposed so that the seed region can interact (by Watson-Crick base pairing) with the 
target mRNA and provide slicer cleavage at a fixed distance due to perfect complementarity 
in the cleavage site (135). Benjamin P. Lewis and coworkers published a paper in 2003 which 
describes an algorithm called TargetScan, for predicting vertebrate miRNA targets. Their 
analysis reinforces the thought that the seed region is the most conserved portion among 
related miRNAs, and has the best inclination for matching numerous conserved segments in 
untranslated regions of mRNA targets (137). Yet,  there are examples of functioning miRNAs 
that lack high binding degree and complementarity in the seed sequence, though this is 
normally required for repression (138). Other regions such as the highly conserved 3‟ 
complementary site or “centered sites” facilitate such action (139). This makes it possible for 
one miRNA to target several mRNAs, as well as different miRNAs regulating the same 
protein-coding gene (140).  
The actions of miRNAs are mediated by argonaute-proteins (AGOs). After binding of the 
miRISC to an RNA-target, regardless of the mode of translational repression,  the AGOs will 
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co-localize to cytoplasmic foci known as processing bodies (P-bodies) (141-143). P-bodies 
entail different enzymes that contribute to post-transcriptional decapping and degradation of 
translationally silenced mRNAs in the 5‟ –to 3‟ direction (142, 144). It seems that either as a 
cause or a consequence of inhibited protein synthesis, repression of translation will cause an 
associtation of mRNAs to P-bodies (141). 
The first and rate-limiting step of miRNA-mediated mRNA degradation is poly(A) removal 
by the deadenylase CCR4-NOT, which is accelerated by RISC (145). miRNA-mediated 
repression is also dependent on the GW182 proteins interacting with AGOs, and recruiting 
additional effector complexes required for silencing in human cells (136, 146). GW182 is a 
protein that comprises multiple glycine(G) - tryptophan(W) repeats, an RNA recognition 
motif (RRM), and functions in RISC-mediated silencing correlating to maintenance of P-
bodies (147, 148). The silencing domain of GW182 proteins interact with the poly(A) – 
binding protein (PABP) and the deadenylase complexes. Recruitment of the deadenylase 
complex releases PABP from the mRNA poly(A) tail, causing a halt in mRNA 
circularitzation and enabling translational repression, deadenylation and subsequent mRNA 
degradation (149, 150). 
Athough some studies indicate that miRNAs repress translation before deadenylation and 
mRNA decay, many uncertainties still surround the subject (151). Translational repression 
and deadenylation may be either independent or co-dependent mechanisms for repression, 




Figure 5. miRNA mediated gene silencing. The miRNA guides RISC to its target mRNA. miRISC binds to the 
target 3‟UTR and inhibits gene expression. The direct effect on translation occurs through either 1) repression of 
translation-initiation, resulting in prevention of ribosome association, or 2) inhibition of translation post-
initiation, including premature ribosome drop-off, stalled elongation and protein degradation. Indirect effects on 
translation include 3) promoting deadenylation, resulting in potential degradation of the mRNA. P-bodies are 
cytoplasmic foci enriched with mRNA-dagradation factors, where mRNAs might be stored for subsequent use, 




1.13 MicroRNAs and breast cancer 
 
The first miRNAs were discovered in 1993(154). However it took another seven years before 
it was uncovered that miRNAs are highly conserved in nature and miRNAs became 
recognized as a distinct class of biological regulators (155). Two years later, in 2002, the first 
link between miRNAs and cancer was established. Columbus University researcher Carlo 
Croce identified two microRNAs, miR - 15 and miR- 16, located in a gene cluster on 
chromosome 13 that was found to be deleted in most cases of chronic lymphocytic leukemia 
(CLL). The down-regulation of these microRNAs was found in around 65% of CLL-patients, 
caused by a germ-line mutation in their primary precursor. The assumption that miR-15 and 
miR-16 act as tumor suppressors was later confirmed by Cimmino, Calin and Fabbri et al. 
They showed that the expression of B cell lymphoma 2 (BCL2), a gene inhibiting cell death, 
was down-regulated post-transcriptionally by miR-15 and -16, causing activation of the 
intrinsic apoptosis pathway (156).  
Important steps in cancer development involve initiation, promotion, malignant 
transformation, progression and metastasis (157). miRNAs have been shown to influence 
biological pathways controlling all these steps, and interaction between mRNA and miRNAs 
affect the fate of both normal and diseased cells (158). A study conducted by Calin and 
coworkers found that over 50% of miRNA genes are located in fragile genome-sites and 
cancer related regions, and that several of the miRNAs showing low expression levels in 
cancer samples were located in such deleted regions (159). 
In 2005, Iorio et al. reported abnormal expression of miRNA in human breast cancer. They 
also identified a correlation between miRNAs and specific features of breast cancer such as 
proliferation index, expression of estrogen/progesterone receptors, tumor stage and 
angiogenesis (160).  
miRNAs have been shown to regulate the expression of both oncogenes and tumor suppressor 
genes (161). miRNAs that negatively regulate transcripts encoding tumor suppressor genes 
are often calles oncomiRs. Oncosuppressor miRNAs on the other hand, have oncogenes as 
targets and these miRNA-genes are located in loci subjected to deletions, mutations or other 
abnormalities causing a reduced level of these anti-cancer miRNAs (162). 
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miR-21 is an example of an oncomiR that is often up-regulated in breast cancers and directly 
targets tumor suppressor genes like tropomysin 1 (TPM1), Phosphatase and tensin homolog 
(PTEN) and Programmed Cell Death 4 (PDCD4) (163-165). Furthermore miR-21 has been 
suggested to be involved in the regulation of the RAS oncogene and gene family, 
transforming growth factor beta 1 (TGF-β) protein and receptor, and the previously 
mentioned BCL-2, all components of regulating pathways in cell growth and differentiation, 
adhesion and migration, and cell survival (166-168). High expression of miR-21 is correlated 
with advanced tumor stage, lymph node metastasis, and poor survival in breast cancer 
patients, suggesting that miR-21 might serve as a molecular prognostic marker for breast 
cancer and disease progression (166). 
Another microRNA acting as an oncomiR in breast cancer is miR-155, which is also 
described in lymphoma, viral infections, cardiovascular disease and in solid cancers (169). As 
with miR-21, miR-155 is up-regulated in breast cancer (160), and has a role in cell 
proliferation and apoptosis, as well as mediating TGFβ-induced EMT (169, 170). miR-155 
promotes migration and invasion of mammary gland epithelial cells by targeting the anti-
metastatic protein, RhoA (171), and activates inflammation-associated tumorigenesis by 
targeting the tumor suppressor gene SOCS1 (suppressor of cytokine signaling 1) (172). There 
has also been reported associations between increased miR-155 expression and metastasis, 
invasiveness and high tumor grade, as well as an inverse correlation between miR-155 and 
FOXO3A, associated with resistance to radio,- or chemotherapy (170, 173). Moreover, miR-
155 has been found to be significantly up-regulated in basal-like and estrogen receptor 
negative (ER-) tumors (163), and to have a close association with the breast cancer 
susceptibility gene (BRAC1) (174). This links high miR-155 expression to both invasiveness 
and recurrence of breast tumors and poor prognosis, and a possible role as a prognostic 
marker (169). 
miR-34a is a member of the miR-34 family (miR-34a, -b and -c), but is transcribed from an 
individual chromosomal locus. Although this region is lost in some cancer types (175), 
reduced or diminished expression could also be due to mutations in the tumor suppressor p53 
which positively regulates the transcription of miR-34a (176). The tumor suppressor actions 
of miR-34a involves silencing of target-oncogenes such as cyklin dependent kinase 6 
(CDK6), leading to apoptosis, cell cycle arrest and a halt in tumor cell proliferation (177, 
178). In breast cancer there seems to be a correlation between high levels of miR-34a 
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expression and a lower risk of metastasis and disease recurrence, highlighting miR-34a as a 
possible predictor of a positive clinical outcome (179).  
Similar to miR-34a, miR-31  also show low expression levels in aggressive human breast 
cancer and inhibits several steps in the metastasis cascade, such as metastatic colonization, 
local invasion and survival of cancer cells at distant sites. miR-31 repress several metastasis-
promoting genes, and it has been demonstrated that overexpression of miR-31 alone is 
sufficient for inhibiting metastasis in otherwise aggressive breast cancer cells while inhibition 
leads to metastasis of otherwise non-aggressive breast cancer cells (180).  
The let-7 family members are also a group of tumor suppressor miRNAs that is frequently 
down –regulated in breast cancer (181, 182). The exact role in tumorigenesis is not yet fully 
understood, but let-7 members appear to play a major role in regulating stemness in breast 
cancer (183). and are also implicated in the negative regulation of several other oncogenes 
involved in regulation of cell cycle, -differentiation and -apoptotic pathways (184-186). 
Overall miRNA expression is generally deregulated in all human cancers, including breast 
cancer, and several miRNAs have been identified as possible biomarkers and/or characterized 
as essential regulators of breast cancer development (187). This abnormal expression will, 
accompanied by advancements in individual miRNA profiling technologies, most certainly 




Figure 6. The role of oncosupressor miRNAs and oncomiRs in cancer proliferation, and an overview of 
some miRNAs reported to act as regulators in the DNA damage response, development of normal 
mammary gland, breast cancer initiation, metastasis and therapy resistance. TSG: tumor suppressor gene, 
OncoG: oncogene. Suppressor miRNAs are shown in green, and oncomiRs are shown in red. The figure is 
modified from (155, 158, 189). 
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2 Materials and methods 
 
2.1  Cell lines 
 
The cell-lines used in this thesis were: AU 565, DU 4475, HCC 1187, HCC 1569, HS 578T, 
MA11, MCF 7 and MD-AMB-231. 
The AU565 cell line was derived at the Naval Biosciences Laboratory, Oakland, CA, from a 
pleural effusion of a 43 years old, Caucasian, female patient with breast carcinoma. She had 
been treated with radiation, steroids, Cytoxan and 5-fluorouracil. The AU565 cell line 
amplifies and overexpresses the HER-2-neu oncogene, and expresses the HER-3, HER-4 and 
p53 oncogenes, and is classified as luminal-subtype breast cancer cell line (190). 
The DU4475 cell line was derived from a 70 years old, Caucasian female patient with ductal 
carcinoma (190). The breast cancer cell line is characterized as a basal-A subtype and 
immunomodulatory (IM), and is also triple-negative (31). 
The HCC1187 cell line was derived from a 41 years old, Caucasian, female patient who had 
received chemotherapy. The tumor was classified as stage IIA, grade 3 (T - tumor size, M – 
metastasis to regional lymph nodes, N – metastasis to distant lymph nodes (9)) invasive ductal 
carcinoma. HCC1187 is positive for the epithelial cell specific marker Epithelial Glycoprotein 
2 (EGP2) and for cytokeratin 19. The cells are poorly differentiated and do not express the 
progesterone receptor (PR) or HER2-neu oncogene, but overexpresses p53 (190). The cell 
line is classified as basal-A subtype and IM, and is also triple negative (31). 
The HCC1569 cell line was derived from a 70 years old, black female patient with a germline 
mutation in the FHIT gene, but had no family history of breast cancer. The patient had 
received prior chemotherapy. The tumor was classified as TNM stage IV, grade 3, metaplastic 
carcinoma with 4 out of 18 lymph node metastasis. HCC1569-cells are positive for expression 
of HER2-neu, negative for p53 and poorly differentiated. They are also positive for the 
epithelial cell specific marker EGP2 and cytokeratin 19, and negative for the expression of the 
estrogen receptor (ER) and PR by immunohistochemistry. This breast cancer cell line is 
classified as basal-A subtype (190). 
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The Hs578T cell strain was derived from a breast-carcinoma from a 74 years old, Caucasian 
female, along with the Hs578Bst (which is a normal fibroblast-like line from the same 
patient). Estrogen receptors are not expressed (190), and the cell line is classified as basal-B 
and is triple negative (31). 
MA11 was derived from a 65-year-old Caucasian female, that originated as an invasive 
lobular carcinoma and metastasized to the bone marrow. The tumor was positive for hormone 
receptors ER and PR (191). 
The MCF-7 breast cancer cell line was derived from a metastatic site (pleural effusion). The 
cancer originated as an adenocarcinoma in a 69-year-old Caucasian female. The MCF7 line 
has several characteristics of differentiated mammary epithelium including the ability to 
process estradiol via cytoplasmic estrogen receptors and the capability of forming domes, and 
is classified as luminal subtype. The cells also express the WNT7B oncogene, and genes for 
insulin growth factor binding proteins (45, 190). 
MDA-MB-231 was derived from metastatic site (pleural effusion) of an adenocarcinoma. The 
patient was a 51 years old, Caucasian female. Cells express epidermal growth factor receptor 
(EGFR), transforming growth factor alpha receptor (TGF alpha), the WNT7B oncogene and 
shows mutations in TP53. This breast cancer cell line is classified as basal-B subtype, and is 













Table 1. Summary of cell lines, classification, expression of receptors, age of patient and growth conditions 
used in this paper (45, 190): 









AU565 Luminal - - +  43  RPMI-1640 
+ 10% FBS 
 




DU4475 Basal-A - - - + 70 RPMI-1640 
+ 10% FBS  
Grows in 
suspension 
HCC1187 Basal-A - - - + 41 RPMI-1640 
+ 10% FBS 
 
HCC1569  Basal-A - - +  70 RPMI-1640 
+ 10% FBS 
 




MA11 Basal-B + ?   65 RPMI-1640 
+ 10% FBS 
 
MDAMB231 Basal-B - - - + 51 DMEM + 
10% FBS 
 






2.2  Culture method 
 
The cells were cultured according to the ATCC guidelines (Table 1), and subcultivated 1-3 
times a week for optimal growth conditions. 5 I.U. of penicillin and 5 µg/mL of streptamycin 
were added to the complete growth medium to prevent bacterial growth. Incubation of the 
cells was done in culture conditions of 37°C and 5% CO2.  
 
2.3  Subculturing 
 
Subculturing was carried out by removing the medium and washing the cells with 5-10 ml of 
Phosphate Buffered Saline (PBS, Sigma Aldrich). This was done to ensure the effect of 
trypsin, a serineprotease which breaks the peptide bonds, keeping the cells in aggregates and 
adherent to the culture-flask. After washing, 0,5-2 ml of 0,25% trypsin, 0,03% EDTA solution 
was carefully added. The flask was then allowed to sit at 37°C until the cells detached. Fresh 
culture medium was added to dilute the trypsin. The cells were then aspirated and dispensed 
into a new culture flask at a suitable subcultivation ratio, and the flask was refilled with 
complete growth medium to a volume of 10 ml, 15 ml or 25 ml to T-25, T-75- or T-175-flasks 
respectively. 
 




Dulbecco‟s Modified Eagle‟s 
Medium (DMEM) with 4500 
mg glucose/L 
Sigma-Aldrich®, St. Louis, 
USA 
Methods 2.2 / 2.3 
Roswell Park Memorial 
Institute Medium (RPMI-
1640) 
Sigma-Aldrich®, St. Louis, 
USA 
Methods 2.2 / 2.3 
Fetal Bovine Serum (FBS) BIOCHROM AG Method 2.2 
Penicillin-Streptomycin Sigma-Aldrich®, St. Louis, 
USA 
Method 2.2 




Buffered Saline (PBS) 
Sigma-Aldrich®, St. Louis, 
USA 
Method 2.3 






2.4  Protein Isolation 
 
The medium was first removed and the cells washed with PBS like in subculturing (method 
2.3). Trypsin was added and the cells sat until they detached, before aspirated in new medium 
(10-12 ml). The desired number of cells were then transferred to and grown on a 6 cm dish, 
after measuring and calculating the volume needed for the count of 300000 cells per dish; 
using this formula: 
                           
         
     
  
                                       
                       
 
After an incubation time of about 1-2 days (at 37°C, 5% CO2), the cells were ready for protein 
isolation. First, the medium was removed and the cells were washed with PBS. Secondly, 150 
µl of MKK lysis-buffer was added, and removed after about 1 minute. A scrape was used to 
transfer the lysate to an eppendorf-tube which was then left on ice for 15 minutes and 
vortexed twice (every 5 minutes) on a vortex during this time, before centrifugation (4°C) on 
maximum speed (13.000 rpm) for 10 minutes. The supernatant was transferred to a new 
eppendorf-tube. 
 
2.5  Protein Assay 
 
This assay was carried out according to the Bio-Rad DC Protein Assay protocol, to achieve 
the same amount of protein in each sample for western blot analysis. The assay is based on 
the reaction between protein and copper in an alkaline medium, and the subsequent reduction 




2.6  Preparation of samples for western blot 
 
Results from the protein assay were used to calculate the volume of cell-extract needed for 
each sample. MKK-lysis buffer was used as a filler to get a total volume of 20 µl in each 
sample. To each sample, LDS sample buffer (6 µl) and sample reducing agent (3 µl) was 
added (Table 3). 
 
2.7  Immunoblotting (Western blot) 
 
Immunoblotting (often referred to as western blotting) is a method for separating and 
visualizing proteins firstly by gel electrophoresis (Sodium dodecyl sulfate; SDS-page), and 
then by blotting on a nitrocellulose membrane (a solid support). The separated and 
immobilized proteins, transferred from the gel to the membrane, are then probed with an 
unlabeled specific antibody (polyclonal or monoclonal) to identify and quantitate any antigens 
present. After being probed with the primary antibody directed against the target protein, the 
membrane is washed and added a labeled secondary antibody (produced in a different species 
of animal, raised against the IgGs from the species of animal in which the primary antibody 
was raised). This results in detection of the present primary antibody, and thus the target 
protein. The results are then read on an infrared imaging system (193, 194).  
The polyacrylamide 10 wells-gel (NuPAGE® Novex® Bis-Tris Mini gels, Invitrogen, 
Carlsbad, CA, USA) was transferred to a chamber filled with running buffer (Table 3). To 
each well there was added a sample of protein-lysate (25 µl), MagicMark™ XP standard (2µl) 
or SeeBlue®Plus2 Pre-stained standard (4 µl) (see Appendix II), after which the gel was run 
on the PowerEase® 500 (Invitrogen, NY, Life technologies
TM
), on 200 V for 40 minutes. 
The blotting materials consisted of a 7,5x7 cm nitrocellulose membrane (Oddyssey 
Nitrocellulose Membrane, LI-COR Bioscience), filter paper (8 x 8 cm), pads and blotting 
buffer (Table 3). The polyacrylamide gel was transferred to the membrane, which was then 
covered with a filter paper on each side. This “sandwich” was kept moist with blotting buffer, 
and held together by several pads in a blotting chamber, and run on the PowerEase®500 for 
1,5 hours on 21 V. 
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Blocking was carried out by transferring the membrane to a centrifuge-tube containing 5 ml 
of commercial blocking buffer (Odyssey, Table 3) for the duration of 1 hour on a turning 
wheel. A dilution of the primary antibody (Table 3) with TWEEN® 20 and blocking buffer 
(1:500) was prepared in a BD-Falcon tube, and added to the membrane after discarding the 
commercial blocking buffer. This was further incubated on rotation for at least 12 hours. The 
membrane was then washed four times (5 minutes each) with TBS (Table 3), before adding the 
secondary antibody (Table 3), diluted in TWEEN® 20 and blocking buffer (1:20000). This 
was incubated for 1 hour wrapped in aluminum foil, followed by another round of washing 
with TBS. 
The membrane was scanned using The Odyssey®Sa Infrared Imaging System. The results 
were gathered by the Odyssey®Sa Software pertaining to this imaging system. 
 
 




MAPKK Lysis buffer Made at the University of 
Tromsø (UiT) 
To 100 mL: 20 mM Tris (pH 
7,0), 1% Triton X-100, 5 mM 
Tetra-sodium pyrophosphate 
(NaPPi), 50 mM NaF, 1 mM 
EDTA, 1 mM EGTA, 1 mM 
vanadate (VO4
2-
), 0,27 M 
Sukrose, 10 mM β-
Glycerophosphate, ad 
ddH2O. 
Methods 2.4, 2.5 and 2.6 
Nupage® LDS sample buffer 
4X 
Invitrogen, NY, Life 
technologies™ 
Method 2.6 
Nupage® Sample reducing 
agent 





Invitrogen, NY, Life 
technologies™ 
Method 2.7 
MagickMark™ XP Western 
Protein standard 
Invitrogen, NY, Life 
technologies™ 
Method 2.7 
NuPAGE® MES SDS 
Running Buffer (20X) 
Invitrogen, NY, Life 
technologies™ 
Method 2.7 
Blotting buffer Contains: 29 g Tris base, 144 
g glycine, 1 L methanol and 




Odyssey Blocking buffer LI-COR Bioscience Method 2.7 
Washing buffer 
Tris Buffered Saline (TBS, 
10X) 
Contains: 2 g KCl, 80 g 
NaCl, 40 mL Tris pH=7,5 
(UiT) 
Method 2.7 
Primary antibody ERK3 ERK3 Abnova Method 2.7 
Primary antibody MK5 MK5-A7 Method 2.7 
Secondary antibody 800 CW anti-mouse Method 2.7 
Primary antibody Actin Anti-actin Method 2.7 




2.8  A search for putative miRNA-targets 
 
A search was carried out from different databases to discover putative miRNA targets for the 
potential binding sites in the 3‟UTR-region of the genes MAPK4 (ERK4), MAPK6 (ERK3) 
and MAPKAPK5 (MK5) (see Appendix I and III). 
The first step was to find the official symbol belonging to the genes coding for the proteins 
ERK3, ERK4 and MK5. National Center for Biotechnology Information (NCBI) was used for 
this search (195). 
Identification of miRNA was carried out from three different databases; TargetScanHuman 
(196), microRNA.org (197) and DIANA LAB (198). The results from these searches were 
gathered and compared to find common miRNA‟s. The target-sequence of the current 
miRNAs was then compared to the 3‟UTR-fragment sequences used in the 3‟UTR Lenti 
GoClones, as seen in Table 4. 
 
2.9  miRNA mimics 
 
miRNAs are implied to regulate protein-coding genes in a non-specific manner. They may act 
on all gene motifs that match their highly conserved seed site, giving miRNA-mediated 
regulation of genes and mRNAs several possible outcomes. In an experimental setting trying 
to silence a specific gene, one approach is to utilize synthetic miRNA-like RNA fragments 
called miRNA mimics. These fragments mimic endogenous miRNAs by having nucleotides 
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1-8 of their 5‟end designed fully complementary to a motif in the 3‟UTR of the target-gene. 
Potential binding to the target-gene will then cause translational inhibition, and because 
miRNA mimics have a reduced number of target sites compared to endogenous miRNAs, 
there is a lower risk of unwanted interference (139). We ordered the putative miRNA mimics 
from Shanghai GenePharma, to screen for miRNAs which could regulate the expression of 
the genes MAPK4, MAPK6 and MAPKAPK5. The GenePharma miRNAs are chemically 
designed and optimized single-stranded nucleic acids, designed to mimic endogenous mature 
miRNAs entering directly into the miRNA processing pathway and having the same actions in 
cells (199). Our search for putative miRNA-targets (method 2.8) provided sense-sequences 
needed for ordering the desired miRNAs, summarized in Table 4. 
 
 
Table 4. miRNA mimics used in transfection experiments (ordered from Shanghai GenePharma Co, Ltd): 




































MAPK4: Mitogen activated protein kinase 4, ERK4: Extracellular signal-regulated kinase 4, MAPK6: Mitogen 
activated protein kinase 6, ERK3: Extracellular signal-regulated kinase 3, MAPKAPK5: MAPK activated protein 
kinase 5 (MK5) 
 
2.10 Transfection of miRNA mimics 
 
Transfection is a method for introducing functional genetic material into eukaryotic cells to 
study gene regulation and expression, cell-signaling, and is also used to inhibit or block the 
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expression of genes by siRNA. Lipofectamine 2000 is a cationic lipid reagent which is used 
(with a dedicated transfection medium like Opti-MEM) for transfecting genomic material into 
adherent cells. The cationic lipids interact with the negative charges of DNA, RNA or 
oligonucleotides, forming a compact structure. The condensed aggregates can interact with, 
and cross, the negatively charged cell membrane into the target cells due to  the positive 
charge and lipophilic nature of cationic lipids (200). 
HEK-293T cells, a highly transfectable derivative of human embryonic kidney 293 cells 
(ATCC® CRL-3216™) were used for transfection.  The cells were cultured according to the 
ATCC guidelines, as described in methods 2.2 and 2.3, in DMEM (with 10% FBS, 5 I.U`s 
penicillin and 5 µg/mL streptomycin). Cells were plated in a 6-well plate, either 40000 cells 
per well and cultured for two days to a 70-90% confluence at the time of transfection, or 
plated at 110000 cells per well and reverse transfected simultaneously. Transfection was 
carried out according to the Invitrogen™ by Life Technologies™ protocol for 
Lipofectamine® 2000 Reagent (201). 
 
2.11 Transfection by Lipofectamine® 2000 Reagent 
 
3.75 µl of miRNA mimic (equivalent to 75 pmol) (see Table 4) was diluted in 250 µl Opti-
MEM® medium in different test tubes, and added 250 µl of diluted Lipofectamine® Reagent 
in Opti-MEM® medium (3 µl in 250 µl respectively, per well). This mixture was incubated 
for 20 minutes in room temperature, before the aspirated plated cells were added 500 µl Opti-
MEM® medium prior to carefully adding the RNA – lipid complex (500 µl) to each well. 
After a new incubation period of 4 – 6 hours at 37°C and 5% CO2, 4 ml of complete growth 
serum was added to each well. This was further incubated for two days, at 37°C and 5% CO2, 
before further analysis (201). 
 
2.12 Reverse Transfection by Lipofectamine® 2000 Reagent 
 
For each well, 3.75 µl of miRNA mimic (equivalent to 75 pmol) (see Table 4) was diluted in 
250 µl Opti-MEM® medium in different test tubes, and added 250 µl of diluted 
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Lipofectamine® Reagent in Opti-MEM® medium (3 µl in 250 µl respectively, per well). This 
mixture was incubated for 20 minutes in room temperature, before carefully adding the RNA 
– lipid complex to the dispersed cells still in suspension, before they attached. The transfected 
cells were then incubated at 37 °C with 5% CO2 for two days before further analysis. 
 
2.13 FLOW Cytometry 
 
The transfection efficiency was determined by using FLOW cytometry, which is a technique 
used for examining microscopic particles, like cells, in heterogeneous fluid-samples. The 
FLOW cytometer consists of a light-source, usually a laser, and detectors. Thousands of cells 
per second pass through the laser as a single file of particles, emitting light which is detected 
as forward scatter (by a detector in line with the laser, detecting light at a 20 degree angle), 
and side scatter (by a detector perpendicular to the laser, detecting light at a 90 degree angle). 
The scattering of light and fluorescence is detected as a signal (a current of photons) being 
amplified and converted to a voltage pulse. This voltage pulse gives information about 
particle size (from the intensity of the forward scatter), complexity and granularity (from the 
intensity of the side scatter), and more, over time. By producing unique light scatters the 
particles are sorted by characteristics, and the population of interest can be singled out by 
viewing the results on dual-parameter histograms (202).  
Since reverse transfection is thought to increase cell exposure to transfection complexes 
because of increased amount of exposed cell surface (203) a fluorescent (FAM) – labeled 
miRNA was both transfected (method 2.11) and reverse transfected (method 2.12) in HEKT-
293T cells (ATCC® CRL-3216™), and analyzed in a BD FACSCalibur flow cytometer (BD 
Biosciences, USA). Reverse transfection showed a higher transfection efficiency (see Figure 7 
and appendix V), and this method (method 2.12) was used for further experiments. 
 
2.14 Purification of total RNA 
 
To study the effect of different miRNAs on the mRNA levels of ERK3, ERK4 and MK5, total 
RNA was purified after two days of incubation time from the cells transfected in method 2.12. 
This was done by using RNeasy Plus Mini Kit from Qiagen, according to the manufacturer`s 
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recommendations. After purification, the RNA was eluated with 40 µl of RNase free water. 
The concentration of RNA in the samples was measured with NanoDrop spectrophotometer 
from Thermo Fisher Scientific. 
 
2.15 Reverse transcriptase quantitative PCR (RT-qPCR) 
 
Quantitative PCR is used to detect and quantify gene transcripts. The samples were prepared 
for qPCR by converting the mRNA into complementary DNA (cDNA) through a reverse 
transcriptase (RT) reaction. Eurogentec Reverse Transcriptase Core Kit (Searing, Belgium) 
was used for this reaction, following the technical data sheet supplied. The volumes in the RT 
Reaction Mix were prepared to be sufficient for 400 ng of total RNA per 20 µl RT step, using 
random nonamers as primers. After the RT-reaction, cDNA was diluted in a ratio of 1:2 with 
RNase free water. 
In real-time qPCR the amplification of a PCR product can be detected in a linear fashion over 
a range of PCR cycles. SYBR Green is a dye that has high affinity for double-stranded DNA 
(dsDNA) and low affinity for single-stranded DNA or RNA. When bound to dsDNA, the 
fluorescence yield from SYBR Green will increase with about 1000 fold, and increase 
proportionally with the DNA concentration, allowing real-time monitoring. Stratagenes 
MX3000P instrument was used to measure fluorescence. 
Through the denaturation step, all cDNA becomes single stranded. In the annealing step, the 
primers will hybridize to the target sequence. Specific primers for each target gene (MAPK4, 
MAPK6 and MAPKAPK5) or reference gene (ACTB and TFRC) were added to the samples 
(summarized in table 5). The elongation phase enhances accumulation of dsDNA and the 
fluorescence intensity increases proportionally, determined by the initial concentration of the 
target.  
The amplification plot reflects changes in fluorescence during cycling, and can be used to 
determine the initial copy number by defining the threshold cycle (Ct). Ct is the first cycle 
where the fluorescence can be statistically measured above background. This value has a 
direct correlation to the starting concentration, which means that high template - amounts in 
the sample yields low Ct-values. Since fluorescence only depends on presence of dsDNA, the 
specificity of the reaction is determined by the binding-degree of the primer to the template, 
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initiating DNA replication. The specificity of the primers was tested by generating a 
dissociation profile. The samples were subjected to a stepwise increase in temperature (from 
55°C to 95°C), and fluorescence was plotted against temperature. The products will melt 
according to their composition, and give a drop in fluorescence due to dissociation of SYBR 
Green. So, if the samples are contaminated or contain primer-dimers or other non-specific 
products, their melting temperature is usually lower than that of the desired products. This 
will show as separate peaks in the dissociation plot (204, 205). 
By using a mathematical formula called the comparative Ct – method (ΔΔCt – method), the 
relative amount of mRNA in each sample can be calculated: 
        
        
 
                     
                     
       
where Ctindex is the average of the Ct-values for the reference genes (ACTB and TFRC), and 
Cttarget is the Ct-value for the target gene (206).  
cDNA equivalent to 40 ng of total RNA was amplified in a total of 25 µl of  Brilliant II 
SYBR® Green PCR-mix (Agilent Technologies, California, USA) with 0,3 µM of forward 
and reverse primers (see Table 5). The primer for one of the reference genes (TFRC) was 
added in a ratio of 1:20 of the total PCR Master Mix volume of 25 µl (see Table 5). The PCR 
was run with the following conditions: 95°C for 15 minutes, following 40 cycles of 94°C for 
15 seconds, 55°C for 30 seconds and 72°C for 30 seconds. To make sure that the samples did 
not contain genomic DNA, the setup included a NoRT – control (samples lacking the reverse 
transcriptase). To rule out contamination of the PCR Master Mix there was also included a 










Table 5. Primer assays used in SYBR
®
 Green-based expression analysis of individual genes: 
Gene symbol Primer-pair ID / Assay 
name 
Production company 
MAPK4 (ERK4) H_MAPK4_1 Sigma-Aldrich®, St. Louis, 
USA 
MAPK6 (ERK3) H_MAPK6_1 Sigma-Aldrich®, St. Louis, 
USA 
MAPKAPK5 (MK5) H_MAPKAPK5_1 Sigma-Aldrich®, St. Louis, 
USA 
ACTB H_ACTB_1 Sigma-Aldrich®, St. Louis, 
USA 
TFRC Hs_TFRC_1_SG QIAGEN 
 
MAPK4: Mitogen activated protein kinase 4 (ERK4), MAPK6: Mitogen activated protein kinase 6 
(ERK3), MAPKAPK5: MAPK activated protein kinase 5 (MK5), ACTB: β-actin, TFRC: Transferrin 
receptor. 
 
2.16 Mission® 3’UTR Lenti GoClone™ 
 
To study a potential regulatory the effect of different miRNAs on the ERK3, ERK4 and MK5, 
HEK-293T cells were transduced with Mission® 3‟UTR Lenti GoClone™ (SwitchGear 
Genomics) constructs harboring parts of the ERK3, ERK4 and MK5 3‟UTRs fused to a 
luciferase reporter gene (RenSP) and a gene for puromycin resistance (Puro) (see appendix I). 
A wide range of mammalian cell lines can achieve stable expression due to the ability of the 
lentivirus backbone to infect several cell culture lines, overcoming low transfection 
difficulties. The viral particles are self-inactivating and replication incompetent, and the 
lentiviral constructs were delivered in HEK293T packaging cells. Each construct, in volumes 
of 0,2 ml with ≥ 10
5
 transducing units, was provided in DMEM with 10% heat inactivated 
FBS and penicillin-streptomycin. The Sigma-Aldrich® SwitchGear Genomics Mission® 
3‟UTR Lenti GoClone™ Technical Bulletin was followed as protocol (207).  
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On day 1, HEK-293T cells (ATCC® CRL-3216™) were plated (10000 cells per well) in a 24-
well plate, in complete medium (DMEM with 10% FBS, 5 I.U`s penicillin and 5 µg/mL 
streptomycin). On day 2, the lentiviral stocks were thawed on ice. Hexadimethrine bromide 
(70 mg/ml) was added to the plated HEK-293T cells, at a final concentration of 8µg/ml, to 
enhance transduction, following addition of viral particles at a volume of 0,1ml (≥ 5∙10
4
 
transducing units). On day 3, the viral-particle containing medium was replaced with pre-
warmed complete culture medium (DMEM with 10% FBS, 5 I.U`s penicillin and 5 µg/mL 
streptomycin). On day 5, the medium was replaced with fresh puromycin-containing medium 
at a concentration of 1,5 µg/ml, for puromycin selection of cells transduced with Mission 
3‟UTR Lenti GoClones. After 3 subsequent days the viral-particle containing cells were 
subcultured and dispensed into a 6-well plate, and further cultured in puromycin containing 
medium (1,5 µg/ml) (Sigma-Aldrich®, St. Louis, USA) until populations of puromycin-
resistant cells were established. Stable integration was confirmed by Dual - Luciferase® 
Reporter Assay (method 2.17) before carrying out further experiments. A control was also 
included in this step, which contained only HEK-293T cells (no transducing units), but was 
added hexadimethrine bromide and cultured in the same puromycin-containing medium as the 
others. This was done to show that non-transduced cells did not show puromycin-resistance 
and would not survive. 
 
Table 6. Summary of the Mission® 3’UTR Lenti GoClone™ used in experiments 2.16 and 2.17: 
Gene name Cat. No. Production 
company/contents/cat.no. 
Experiment 
MAPK4 HUTR10812 SwitchGear Genomics, 
Sigma-Aldrich®, St. Louis, 
USA 
2.13 and 2.14 
MAPK6 HUTR08621 SwitchGear Genomics, 
Sigma-Aldrich®, St. Louis, 
USA 
2.13 and 2.14 
MAPKAPK5 HUTR03385 SwitchGear Genomics, 
Sigma-Aldrich®, St. Louis, 
USA 
2.13 and 2.14 
N.T. Control HUTR003C SwitchGear Genomics, 
Sigma-Aldrich®, St. Louis, 
USA 
2.13 and 2.14 
 
MAPK4: Mitogen activated protein kinase 4, MAPK6: Mitogen activated protein kinase 6, MAPKAPK5: MAPK 
activated protein kinase 5, N.T. Control: Non Target Contro 
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2.17 Dual - Luciferase® Reporter Assay System 
 
To study the gene expression of MAPK4, MAPK6 and MAPKAPK5 transfected with selected 
miRNAs, we applied the Dual-Luciferase® Reporter (DLR™) Assay System where two 
individual reporter enzymes are measured simultaneously within a single system. The main 
reporter, in this case Renilla luciferase, correlates with the gene expression of the target-
genes. Renilla luciferase is a 36 kDa monomeric protein and functions as a genetic reporter 
right after translation. The control reporter, in this case Firefly luciferase, serves as an internal 
control. Firefly luciferase is a 61 kDa monomeric protein that in the same way as Renilla 
luciferase has enzymatic activity without post-translational processing. Both yield 
luminescence by photon emission through oxidation, but can be discriminated between 
because of their different enzyme structures and the substrates needed for their 
bioluminescent reactions (208). 
The cells containing stably transduced Mission 3‟UTR Lenti GoClones (from method 2.16) 
were plated out in 6-well plates, as described in method 2.10, with 110000 cells per well and 
1,5 µg/ml puromycin-containing medium (as used in method 2.16). Included in the 
experiment was a control vector construct with a non-specific 3‟UTR, containing non-
conserved, non-genic and non-repetitive human genomic fragments. Each construct was then 
reverse transfected with the corresponding miRNAs (see Table 4) as described in method 
2.12. After two days the cells were lysed by adding diluted Passive Lysis 5x Buffer 
(Promega), which gives rapid lysis of cultured mammalian cells without scraping. 
The growth medium was removed from the cultured cells, and washed with phosphate 
buffered saline (see Table 2). The rinse was completely removed before adding 500 µl of 
1xPLB (3 ml Passive Lysis 5x Buffer diluted in 12 ml distilled water) to each well. The lysis 
buffer was allowed to work for 15 minutes on a rocking platform in room temperature, before 
transferring the lysates into individual tubes. Lysate samples were cleared for 30 seconds at 
top speed in a refrigerated micro-centrifuge, and 20 µl of each sample was transferred to 
individual wells in a 96-well plate. Following the Dual-Luciferase® Reporter Assay Protocol, 
100 µl Luciferase Assay Reagent II (LAR II) was dispensed by a reagent injector into each 
sample-well. This measures the firefly luciferase, and generates a stabilized luminescent 
signal. Straight after the firefly reaction is quenched, the Renilla luciferase reaction is initiated 
by the reagent injector adding 100 µl Stop & Glo® Reagent into the same sample-wells, 
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giving stabilized luminescence from the Renilla luciferase. Rapid quantitation of both 
reporters yields linear assays, and luminescence was detected in the Thermo Scientific™ 
Luminoskan Ascent Microplate Luminometer (Thermo Scientific). Ascent Software for 




3.1  Optimization of miRNA transfection efficiency 
In experiments directed at miRNA target identification, it is important to use conditions that 
result in highest transduction efficiency, to maximize the level of inhibition on mRNA and/or 
protein expression. To investigate the influence of two different transfection methods on 
tranfection efficiency, FAM™- Dye Labeled miRNA-mimics and negative control miRNA-
mimics were transfected by using Lipofectamine® 2000 reagent (method 2.11 and 2.12) in 
HEK-293T cells (ATCC® CRL-3216™). The FAM™ Dye is a fluorescent label that has been 
extensively tested in human cell lines and tissues and validated to produce no identifiable 
effects on known miRNA function. It is used for monitoring transfection efficiency in 
transfection experiments and enables direct observation of cellular uptake.  
Both conditions resulted in the presence of a fluorescent signal in a high percentage of cells 
and no cytotoxicity was observed after 48 hours.  The results from the flow-cytometry 
(method 2.13) showed a pronounced difference in transfection efficiency when comparing 
regular transfection (method 2.11) and reverse transfection (method 2.12) as seen in Figure 7. 
The average positive transfected cells were almost 100% with reverse transfection, compared 




Figure 7. Flow cytometry to evaluate transfection efficiency of miRNA-mimics in HEK-293T cells 
comparing regular- and reverse transfection. N.C. miRNA mimic: negative control miRNA mimic (not 
labeled by fluorescent dye) is compared to FAM-miRNA mimic: miRNA-mimic labeled by fluorescent dye 
using two different methods of transfection. 
 
3.2  MK5 and ERK3 are expressed in breast cancer cell-lines 
 
The mitogen-activated protein (MAP) kinase pathways have been implicated to play an 
important role in many cancers, including breast cancer (209). Tumorigenic processes may 
also involve the atypical MAP kinases ERK3/4 and MK5 and studies have shown that these 
kinases can participate in several processes that are deregulated in cancer, including cell 
proliferation, cell motility, invasiveness, and angiogenesis (60, 61, 210, 211). The ras, raf and 
c-myc genes are commonly mutated in cancer, and ERK3/4 and MK5 seem to act downstream 
of the Ras/Raf pathway and are also implicated in the regulation of c-Myc expression. 
However, the precise molecular mechanisms of ERK3, ERK4 and MK5 in cancer and cancer-
related signaling pathways remains to be unraveled (209).  
 
There is little knowledge surrounding regulation of the atypical MAP kinases, and their 
correlation to breast cancer. To investigate and compare the relative expression level of ERK 
3 (~ 100 kDa) (212), and its substrate MK5 (~ 54kDa) (64), we used the method of western 
blotting analysis in 8 different breast cancer cell lines (BCCL) belonging to all three 








N.C. miRNA mimic FAM-miRNA mimic N.C. RNA mimic FAM-miRNA mimic
Regular transfection Reverse transfection
Transfection efficiency in HEK-293T cells 
Average negative (%) Average positive (%)
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to detect ERK4 by a regular western blot, so this protein was excluded from these initial 
analyses. 
 
In order to ensure equal loading, the blots were also probed with anti-actin antibody, however 
the expression-level of actin in the different breast cancer cell lines varied far more than 
expected (see appendix VI) considering that a protein assay had been conducted prior to the 
western blot analysis to achieve the same amount of protein in each sample. Since we could 
not rule out the possibility of different levels of actin in our cell lines (which is a well-known 
phenomenon (213)), we chose to compare the integrated intensities from each cell line 
directly, for both the MK5 and ERK3 blots. 
 
Results of the western blot analysis (figures Figure 8 and Figure 9) show that both ERK3 and 
MK5 are present in all the breast cancer cell lines, however the expression level varies greatly 
and does not correlate with their molecular subtype. The western blot also shows the presence 
of two different bands located at around 80 – and 100 kDa for ERK3 and two bands at around 
54- and 70 kDa for MK5. The bands at around 80- and 70 kDa are probably caused by 
unspecific binding by the antibodies in the ERK3 and MK5 experiments respectively. 
Our results confirm the presence of ERK3 and MK5 in all breast cancer cell lines tested, 
however little is known about the ERK3, ERK4 and MK5 protein levels in breast cancer (and 
in cancers in general), and it remains to be established whether aberrant expression of these 








Figure 8. Expression of ERK3 in breast cancer cell lines. 300000 cells/dish were grown in a 6-cm-dish for 1-2 
days before they were lysed. Proteins were measured in a protein assay prior to western blot analysis. ERK3 
Abnova (1:500) was used as primary antibody and 800 CW anti-mouse (1:20000) was used as secondary 
antibody. A) Western Blot of the ERK3 protein expression in different breast cancer cell lines. B) Quantification 
of the western blot show variations in the expression of ERK3 proteins between different breast cancer cell lines, 
classified into subtypes by color: Luminal: blue, Basal-A: green, Basal-B: red. 
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Figure 9. Expression of MK5 in breast cancer cell lines. 300000 cells/dish were grown in a 6-cm-dish for 1-2 
days before they were lysed. Proteins were measured in a protein assay prior to western blot analysis. MK5-A7 
(1:500) was used as primary antibody and 800 CW anti-mouse (1:20000) was used as secondary antibody. A) 
Western Blot of the MK5 protein expression in different breast cancer cell lines. In this western blot, the cell line 
MDAMB231 is not comparable due to a low protein count.  B) Western blot with the samples from blot A, 
except for a new protein assay of MDAMB231, to achieve a comparable result. This immunoblot is missing the 
cell line HCC1187 due to small sample size. Quantification of the western blot show variations in the expression 
of the MK5 C) Quantification of the western blots shows variations in the expression of MK5 between the 
different breast cancer cell lines, classified into subtypes by color: Luminal: blue, Basal-A: green, Basal-B: red. 
The column-diagram is showing the combined integrated intensities of blot A) and B), with SEM. 
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3.3  The mRNA levels of ERK3/4 and MK5 are not significantly affected by 
miRNAs predicted to bind in their 3’UTR 
 
Regulation of cellular signaling pathways, such as the mitogen-activated protein (MAP) 
kinase pathways, involves miRNAs. These small RNA-molecules silence genes at either 
transcriptional or translational levels, often by targeting their 3‟-untranslated regions. A single 
miRNA can be predicted to target several hundred genes, and about 60% of mRNAs have 
predicted binding sites for one or multiple miRNAs in their 3‟UTR (92, 126, 214). The 
function of a miRNA is ultimately defined by the genes it targets and its effects on their 
expression. In cancer cells and breast cancer cell lines there seems to be an abnormal 
expression of miRNAs, and such an imbalance is closely related to malignant proliferation 
and migration of cancer cells. miRNAs may act as oncogenes or tumor suppressors, but their 
exact role in specific steps of malignant progression is not yet known (215). 
As mentioned in part 3.2, little is known about the regulation and function of ERK3/ERK4.  It 
has been shown that both ERK3 and ERK4 can activate MK5. MK5 in turn, phosphorylates 
transcription factor FOXO3a, which leads to an increased level of mir34b/c. mir34b/c inhibits 
the cell cycle and prevents translation of c-myc mRNA (211). However, currently no other 
miRNAs have been linked to the regulation of this ERK3/4-MK5 atypical MAP kinase 
signalling pathway. A number of freely available programs predict potential mRNA targets 
for individual miRNAs in silico. However the predictions must be confirmed using miRNA 
target validation techniques that aim to detect changes in mRNA and/or protein level in 
response to miRNA overexpression. 
 
In order to investigate if the expression of eitherERK3, ERK4 or MK5 may be regulated by 
miRNAs, we selected 16 different miRNAs with potential binding target sites (predicted by 
the TargetScanHuman, microRNA.org and DIANA LAB bioinformatics approaches) in the 
3‟UTR of the mRNAs (see Table 7). Since miRNA target silencing can occur both at the level 
of translation and mRNA degradation, we aimed to investigate if the expression of our 
selected miRNAs would affect the mRNA levels of ERK3, ERK4 and MK5 in HEK-293T 






Table 7. miRNA mimics used in transfection experiments (ordered from Shanghai GenePharma Co, Ltd): 




































MAPK4 is the gene for which the mitogen activated protein kinase 4, ERK4, is encoded. MAPK6 it the gene for 
which mitogen activated protein kinase 6, ERK3 is encoded and MAPKAPK5 is the gene for which MAPK 
activated protein kinase 5, MK5 is encoded. 
 
The HEK-293T cells were transfected with the miRNAs with potential binding properties for 
ERK3, ERK4 and MK5 mRNA 3‟UTRs (see Table 7), and negative control miRNA (N.C. 
miRNA) without binding-potential. We also included non-transfected HEK-293T cells (N.T. 
HEK). Two days after transfection, total RNA was extracted from the HEK-293T cells (three 
biological replicates per mimic miRNA) using the RNeasy Plus Mini Kit from Qiagen, 
according to the manufacturer‟s recommendations. First strand cDNA synthesis was done on 
400 ng total RNA per reaction using the Reverse Transcriptase Core Kit (Eurogentec) and 
mRNA levels were quantified using qRT-PCR with Brilliant II SYBR® Green PCR-mix 
(Agilent Technologies) on Stratagenes Mx300P QPCR System Instrument (Agilent 
Technologies), with normalization of gene expression to the reference (housekeeping) genes 
ACTB and TFRC.  
 
Figure 10 shows the relative amount of ERK4 mRNA after reverse transfection of miR-423-
5p, miR-922, miR-34c-5p and miR-124-5p, related to the negative control miRNA (N.C. 
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miRNA). No significant effect of any of the four miRNAs was observed on the levels of 




Figure 10. Expression of ERK4 mRNA. RT-(q)PCR analysis of ERK4 mRNA expression in HEK-293T cells 
transfected with four different miRNAs with potential binding target sites in the 3‟UTR of the ERK4 mRNA. 
Expression levels of mRNA was determined in individual samples by RT-qPCR. Fold changes compared with 
the internal controls were calculated based on the ΔΔCt – method. Data represented as the means ± SEM. 
 
Figure 11 shows the relative amount of ERK3 mRNA after reverse transfection of miR-26a-
5p, miR-26b-5p, miR-302a-5p, miR-425 and miR-1297, related to the negative control 
miRNA (N.C. miRNA). Although the standard deviation of the negative control miRNA is 
substantial, the mean value is similar to the second internal control (non-transfected HEK-
293T cells) and was considered to still serve as the relating control. We observed no 








































Figure 11, Expression of ERK3 mRNA. RT-(q)PCR analysis of ERK3 mRNA expression in HEK-293T cells 
transfected with five different miRNAs with potential binding target sites in the 3‟UTR of the ERK3 mRNA. 
Expression levels of mRNA was determined in individual samples by RT-qPCR. Fold changes compared with 
the internal controls were calculated based on the ΔΔCt – method. Data represented as the means ± SEM. 
 
 
Figure 12. A shows the relative amount of MK5 mRNA after reverse transfection of miR-517-
b, miR-944, miR-1284 and miR-1305, related to the negative control miRNA (N.C. miRNA). 
Figure 12.B shows the relative amount of MK5 mRNA after reverse transfection of miR-
548d, miR-518-d and miR-559 related to the N.C. miRNA. Here, no significant change of the 
MK5 mRNA level was observed by any of the miRNAs with potential binding target sites in 
the MK5 3‟UTR. 
The results from these experiments show that neither of the miRNAs with in silico predicted 
target sites in the 3‟UTR of each of the three atypical MAPKs (summarized in Table 7) 
caused a significant decrease in cellular mRNA level of these kinases. However, this does not 








































Figure 12. Expression of MK5 mRNA. RT-(q)PCR analysis of MK5 mRNA expression in HEK-293T cells 
transfected with seven different miRNAs with potential binding target sites in the 3‟UTR of the MK5 mRNA in 
two separate experiments (A and B). Expression levels of mRNA was determined in individual samples by RT-
qPCR. Fold changes compared with the internal controls were calculated based on the ΔΔCt – method. Data 







































































3.4  A potential regulation of ERK3 and MK5 protein levels by miRNAs predicted 
to bind in the ERK3 and MK5 3’UTR 
If a given mRNA is a true target of a specific miRNA, then change in the miRNA expression 
should correspond to a predictable change in the amount of protein encoded by the target 
mRNA. The most commonly used approach to verify a miRNA target site is by linking the 
mRNA target to a luciferase reporter. A change in luciferase protein level will indicate 
whether a miRNA can bind to the 3‟UTR and regulate the expression of the gene at the 
protein level.  
To determine if any of our selected miRNAs act to regulate ERK3, ERK4 or MK5 at the level 
of translation, a renilla luciferase reporter assay was conducted (method 2.17). Prior to the 
experiments, we established four different HEK293T cell lines containing viral vectors (Lenti 
GoClone) that stably express a luciferase reporter gene (RenSP) fused to a part of the ERK3-, 
ERK4- or MK5 3‟UTR sequences, and a positive control vector lacking a 3‟UTR sequence 
(P.C. construct) in method 2.16.  
The stably transfected cell lines containing the ERK3-, ERK4- or MK5 3‟UTR fused to 
RenSP were reverse transfected with the pertaining miRNAs, including a negative control 
miRNA (N.C. miRNA). We also included the cell line harboring the positive control vector 
(P.C. construct) and a non-transfected control (N.T. control) for each of the three experiments 
(method 2.12). Due to limited time only one biological replicate, and two technical replicates 
was carried out. As a result of extremely large variations within each sample-replicate in parts 
of the experiment, the first technical replicate was not included in these results. 
Figure 13. shows the relative luciferase activity in the HEK293Tcells expressing ERK4 
3‟UTR- RenSP, 48 hours after reverse transfection with miR-423-5p, miR-922, miR-34c-5p 
and miR-124-5p. As seen in the figure, there is no significant change in the relative luciferase 
activity in the transfected constructs compared to the controls for any of the miRNAs. This 
clearly indicates that none of the chosen miRNAs binds to this part of the ERK4 3‟UTR and 




Figure 13. Relative luciferase activity in HEK293T cells expressing ERK4 3’UTR- RenSP reporter 
plasmids transfected with pertaining miRNAs or negative control miRNA (N.C. miRNA), no miRNA (N.T. 
control) or positive control vector (P.C. construct). Luciferase activity was measured 48 h transfection. 
Values are presented as mean relative luciferase activity ± SEM. 
 
Figure 14. shows the relative luciferase activity in the HEK293Tcells expressing ERK3 
3‟UTR- RenSP 48 hours after reverse transfection with miR-26a-5p, miR-26b-5p, miR-302a-
5p, miR-425 and miR-1297. Due to huge variations in the relative luciferase activity in the 
N.T control and a fairly low relative luciferase activity in the N.C miRNA control, it is 
difficult to draw any firm conclusions from this experiment. If we choose to relate the 
miRNAs with potential binding sites in ERK3 3‟UTR to the N.C miRNA, the expression of 
miR-26a-5p, miR-425 and miR-1297 seems to cause an up-regulation of the luciferase 
expression. However, if we choose to relate the relative luciferase expression to the positive 
control vector (lacking a 3‟UTR sequence, P.C. construct), the expression of miR-26b-5p and 
miR-302a-5p cause a down-regulation of the luciferase expression. Since the relative 
luciferase activity of the cells transfected with miR-26a-5p, miR-425 and miR-1297 are 
comparable to that of the P.C. construct, it seems more likely that the correct interpretation of 
these results is a potential binding to the ERK3 3‟UTR by miR-26b-5p and miR-302a-5p 



































Figure 14. Relative luciferase activity in HEK293T cells expressing ERK3 3’UTR- RenSP reporter 
plasmids transfected with pertaining miRNAs or negative control miRNA (N.C. miRNA), no miRNA (N.T. 
control) or positive control vector (P.C. construct). Luciferase activity was measured 48 h after transfection. 
Values are presented as mean relative luciferase activity ± SEM. 
 
Figure 15. shows the relative luciferase activity in the HEK293Tcells expressing MK5 
3‟UTR- RenSP 48 hours after reverse transfection with miR-517-b, miR-944, miR-1284, 
miR-1305, miR-548d, miR-518-d and miR-559. Due to a substantial difference in the relative 
luciferase activity between the negative control miRNA (N.C. miRNA) and the non-
transfected control (N.T. control), which had a quite low luciferase activity, it is also difficult 
to draw any firm conclusions from these results. Since the relative luciferase activity for the 
N.C. miRNA is similar to the luciferase activity of the positive control vector (P.C. construct), 
it seems more likely that the N.C. miRNA and P.C. construct represent the correct 
measurements, while the N.T. control may have been compromised in the experimental 
process or during the luciferase assay.  
If we choose to relate the miRNAs with potential binding sites in MK5 3‟UTR to the N.C 
miRNA and the P.C. construct, the expression of miR-1305 seems to cause a slight up-
regulation of the luciferase expression. In contrast, the expression of miR-517-b, and miR-
548d-5p, miR-518-d-5p and miR-559 appear to cause a down-regulation of the luciferase 
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expressions to that of the N.C. miRNA and the P.C. construct, underscoring the probability 
that the correct interpretation of these results is a potential binding of miR-517-b, and miR-
548d-5p, miR-518-d-5p and miR-559 to the MK5 3‟UTR. 
 
 
Figure 15. Relative luciferase activity in HEK293T cells expressing MK5 3’UTR- RenSP reporter 
plasmids transfected with pertaining miRNAs or negative control miRNA (N.C. miRNA), no miRNA or 
positive control vector (P.C. construct). Luciferase activity was measured 48 h after transfection. Values are 
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3.5  A potential correlation between the expression of miRNA predicted to bind in 
the 3’UTR of ERK3 and MK5, and ERK3 and MK5 protein expressions in 
different subtypes of breast cancer cell lines. 
 
Although the ERK3/4-MK5 pathway has been implicated in processes involved in cancer 
development and progress, in general there is not much knowledge surrounding these atypical 
protein kinases, as to how they are regulated or what their targets are (209). 
The diverging expression of developmental genes is often seen as a cause of diseases, such as 
cancer (184). In the regulation of cancer development there seems to be a common pattern 
shared by miRNAs and  protein oncogenes and tumor suppressors (216, 217), but the 
relationship between cell signaling pathways and the miRNA pathway is not well understood 
(218). A report from 2009 described a connection between miRNA expression and the 
Raf/MAPK/Erk pathway, suggesting a potential regulation by the let-7 miRNA-family (219). 
Another study has also shown a connection between the miRNA-generating complex and the 
MAPK/Erk pathway. The authors found that to effect mitogenic signaling, the MAPK/ERK 
kinases act on the miRNA-generating complex by phosphorylating the transactivating 
response RNA-binding protein (TRBP), participating in Dicer-mediated cleavage of the pre-
miRNA. This phosphorylation lead to enhanced stability of the miRNA-generating complex, 
and resulted in an increased miRNA production and miRNA-mediated gene silencing. They 
suggested that through parallel mechanisms, the Raf/MAPK/Erk cascade affect cell signaling 
by regulating the miRNA expression (218). 
Having established that the ERK3 and MK5 atypical kinases are expressed in all breast cancer 
cell lines tested, we wanted to search for a potential connection between the expression of our 
previously selected miRNAs and the protein expression in a biologically relevant system. To 
identify a potential correlation between the expression of the selected miRNAs predicted to 
bind in the 3‟UTR of ERK3 and MK5, (see Table 7) we performed an in silico analysis of the 
expression selected miRNAs (previously obtained by small RNA profiling by Applied 
Biosystem‟s next-generation sequencing system (SOLiD5500™ XL)) and related that 
expression to the pertaining expression of ERK3 and MK5 in the same cell lines (obtained by 




Figure 16 shows the expression of all the miRNAs with predicted binding sites in the 3‟UTR 
of ERK3, ERK4 and MK5.  It seems as these miRNAs belong to one of three groups: those 
that generally are expressed at a high level in all the breast cancer cell lines (BCCL) (miR-
26a, miR-26b and miR-425).  miRNAs expressed, but not highly expressed, in all or most 
BCCL (423-5p, miR-34c-5p, miR-517-b, and miR-548d-5p) or miRNAs that show a very low 
or no expression in any of the cell lines (miR-922, miR-124-5p, miR-302a-5p, miR-1297, 
miR-944, miR-1284, miR-1305, miR-518d-5p, and miR-559). This miRNA expression 
pattern can probably be explained by the fact that miRNAs are highly tissue specific with 
highly variable expression patterns comparing different tissues (220). 
 
 
Figure 16. The expression of selected miRNAs (see Table 7) in the different breast cancer cell lines. The 
tendencies can be divided into three categories; 1) highly expressed in all BCCL, 2) expressed in most BCCL 




























In Figure 17 we show a comparison between the expression of the most highly expressed 
miRNAs for each kinase (ERK3 and MK5), against the expression of ERK3 and MK5 in the 
same breast cancer cell lines.  
 
 
Figure 17. The correlation between the expression of ERK3 or MK5 in the different BCCL, and the 
miRNAs highly expressed or expressed in the same BCCL (see Error! Reference source not found. and Error! 
Reference source not found.). Values on the primary vertical axis are represented as an inverse scale showing the 
expression of ERK3/MK5. The horizontal axis is showing the expression of miRNAs (log values). 
 
For ERK3, we can see that in the majority of the BCCL, there is an inverse correlation 
between the miRNA and the ERK3 expression (see Table 8). This may suggest a possible 
miRNA-mediated regulation of the ERK3 protein level in these BCCL. However a 
































































In the case of MK5, some of the miRNAs had medium to high expression in a few cell lines, 
while in others there was a low, or no expression of our selected miRNAs (see Table 9).  No 
apparent correlation between the expression of MK5 and the miRNAs miR-517-b and miR-
548d-5p (the miRNAs with the highest expressions of our selected in the BCCL (see Figure 
16) was observed. Still, as shown in Table 9, the BCCL with the highest expression of MK5 
(DU4475, MA11 and MCF7) display a very low or no expression of the miRNAs with 
predicted binding sites in the MK5 3‟UTR. This observation may indicate a possible 
correlation between the MK5 expression and the expression of the selected miRNAs; at least 
a potential miRNA-mediated regulation of MK5 in BCCL is not excluded. However such an 
interaction would have to be identified and verified experimentally. Our search for putative 
miRNAs was only based on target sequence complementarity and binding affinity to the 
3‟UTR sequence of our reporter plasmids. The tissue-specific nature of miRNA-function was 
not taken into account. This might be the reason why some of the miRNAs are showing no 
expression in the different BCCL, although it does not rule out the possibility of MK5 
regulation by these miRNAs.  
BCCL ERK3 miR-26a-5p miR-26b-5p miR-425 miR-302a-5p miR-1297 
AU565 1,29 15,02 10,51 12,33 0 0 
DU4475 7,26 11,29 5,61 10,94 0 0 
HCC1187 1,61 10,98 5,46 10,48 0 0 
HCC1569 4,88 12,91 7,66 9,47 0 0 
Hs578T 1,36 12,24 6,89 9,33 0 0 
MA11 1,34 12,01 6,46 10,17 0 0 
MCF7 1,35 11,78 6,81 10,41 0 0 
MDAMB231 2,69 12,54 6,12 11,97 0 0 
Table 8. The expression of ERK 3 and the pertaining miRNAs in different breast cancer cell lines (BCCL). 
miR-26a-5p, miR-26b-5p and miR-425 are highly expressed (also seen in Figure 16), compared to a relatively 
low expression of the ERK 3 protein in the same BCCL. miR-302a-5p and miR-1297 are not expressed in these 
breast cancer cell lines. 





AU565 17,7 9,59 0 0 0 6,16 0 0 
DU4475 18,89 0 0 0 0 0 0 0 
HCC1187 4,02 1,66 0 0 0 2,26 0 0 
HCC1569 9,26 4,24 0 0 0 3,98 0 0 
Hs578T 2,23 8,03 1,91 0 2,22 2,98 0 0 
MA11 18,5 0 0 0 0 0 0 0 
MCF7 11,85 0 0 0 0 2,47 0 0 
MDAMB231 4,04 2,46 1,79 0 0 0 0 0 
Table 9. The expression of MK5 and the pertaining miRNAs in different breast cancer cell lines (BCCL). 
miR-517-b and miR-548d-5p showed a higher expression in several of the breast cancer cell lines than the other 
miRNAs (also seen in Figure 16). The cell lines showing the highest expression of MK5 (DU4475, MA11 and 





Today, most of the physiologic miRNA-targets still remain to be verified experimentally 
(221). Although perfect seed pairing may not be necessary for miRNA – target 3‟UTR 
interaction (222), the approaches that are being used for predicting target genes have a focus 
on identifying the evolutionarily conserved sequence, and comparing complementary 
elements in the targets 3‟UTR to the miRNA seed sequence (223). This generally causes a 
high false positive- and false negative rate, resulting in high percentage of non-functional 
predicted target sites (221, 224). 
 
miRNAs are important regulators of cellular mechanisms, also associated with cancer 
development, such as cell growth, differentiation and apoptosis . The role of each miRNA is 
dependent upon the biological role of their target. The growing discoveries in research and 
identifications of disease-specific miRNAs may lead to new prognostic tools and therapies, as 
well as individualized therapy which would be a huge advantage in such heterogeneous 
diseases as breast cancer. Many miRNA genes have been identified and proven, but there are 
still very few corresponding targets that have been identified and experimentally validated 
(221). 
 
Cellular mechanisms are mediated and regulated in part through extracellular signals being 
conveyed to components inside the cell and cell nucleus. The ERK3/4-MK5 pathway has 
been implicated in processes involved in cancer development and progress, but in general 
there is not much knowledge surrounding these atypical protein kinases, as to how they are 
regulated or what their targets are (209). Extracellular signals for cell growth, survival, 
proliferation and differentiation are relayed through signaling pathways such as the 
MAPK/Erk pathway to intracellular responses, also mediated by the MAPK-activated protein 
kinases (MKs), such as MK5. The MKs are stimulated by mitogenic,- and stress stimuli, and 
are activated through phosphorylation of their kinase domain by extracellular signal-regulated 
kinases 1/ 2 and p38 MAPKs (225). As mentioned earlier, MK5 is also a known substrate of 
the atypical kinases ERK3/4 (63). 
Initially, we wanted to assess the presence of the atypical MAPKs in different breast cancer 
cell lines, so we performed a western blot analysis on 8 different BCCL belonging to 3 
different molecular subtypes (see Table 1). As shown in the results (see Figure 8 and Figure 
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9) we chose to compare the direct integrated intensities between the cell lines in the individual 
blots of ERK3 and MK5. This decision was based on the fact that prior to the western blot 
analysis, we had performed a protein assay to ensure equal loading of the samples, and also 
because the results from normalization with anti-actin antibody showed a larger variation of 
actin-expression in the different breast cancer cell lines than expected. This is a known 
phenomenon, where in disease states and during growth and differentiation, the expression of 
beta-actin can change in response to biochemical stimuli (213). 
Our results showed expression of both ERK3 and MK5 in all of the 8 BCCL, although in 
varying levels. We could not see any correlation between the expression of the kinases and 
the molecular subtypes of the cell lines. For example, the expression of ERK3 varied 
significantly in the basal-A subtype  (DU4475, HCC1187 and HCC1569, marked in green in 
Figure 8), which is associated with cancers that are invasive, aggressive, high grade and have 
poor prognosis and often triple-negative phenotypes (16-18). 
The expression of ERK3 in the other two molecular subtypes of BCCL were much lower, and 
did not vary as much as in the basal-A subgroup. The luminal-subgoup (BCCL AU565 and 
MCF7) is associated with breast tumors that have good prognosis compared to the basal-like 
and ERBB2-positive tumors, although luminal-B differs from luminal-A in that it is HER2-
positive, has a higher proliferative rate and histological grade, giving it a worse prognosis (8, 
13, 14). The basal-B subgroup (Hs578T, MA11 and MDAMB231) also had a lower 
expression of ERK3 than the basal-A subtype of BCCL, with the exception on a slightly 
higher expression in MDAMB231. This subgroup of cell lines is associated with basal-like 
and ERBB2-positive  tumors. They are aggressive, invasive, usually higher grade and have a 
higher risk of earlier relapse (12, 16-18). 
When comparing the expression levels of the MK5 protein in the different BCCL, no 
significant correlation between the molecular subtypes of was observed. HCC1187 (basal-A), 
Hs578T (basal-B) and MDAMB231 (basal-B) had the lowest expression of MK5. AU565 and 
MCF7 (luminal) had a slightly higher overall expression of MK5, however DU4475 (basal-A) 
and MA11 (basal-B) displayed the highest MK5 expression levels. 
Overall, these results demonstrate a general presence of the atypical kinases ERK3 and MK5 
in BCCL of different molecular subtype. Nevertheless, it is difficult to draw any conclusions 
or trends from these results since variations between expressions in each subgropup were so 
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profound, and knowledge suroounding the topic of the atypical kinases and breast cancer is 
very limited. 
Having established the consistent expression of ERK3 and MK5, we wanted to explore a 
potential regulation of the atypical kinase pathway by miRNAs. Indeed miRNAs are involved 
in the regulation of the regular mitogen-activated protein (MAP) kinase pathways both at 
transcriptional or translational levels, and often by targeting their 3‟-untranslated regions (11, 
92). Except for miR-34b/c, no other miRNAs have been linked to the regulation of  ERK3/4-
MK5 atypical MAP kinase signalling pathway (211). 
Through TargetScanHuman, microRNA.org and DIANA LAB bioinformatics approaches, we 
selected 16 different miRNAs with potential binding target sites in the 3‟UTR of the mRNAs 
of ERK3, ERK4 and MK5 (see Table 7). Since miRNA target silencing can occur both at the 
level of translation and mRNA degradation, we first aimed to investigate if the expression of 
our selected miRNAs would affect the mRNA levels of ERK3, ERK4 or MK5 in HEK-293T 
cells by using real-time RT-(q)PCR. 
Our results showed no significant decrease in the cellular mRNA level of either ERK3, ERK4 
or MK5 upon expression of any of the miRNAs with in silico predicted target sites in the 
3‟UTR of each of these kinases (see Figure 10, Figure 11 and Figure 12). However, this did 
not rule out the possibility of regulation through translational repression (95). Notably, the 
selection of our putative miRNAs was based on the potential binding-interactions to the 
truncated 3‟UTR-sequence in the Mission LentiGoClone constructs. The fact that the 
available sequence was missing parts of the 3‟UTR for ERK3/4 and MK5 mRNAs, limited 
our options in the search for putative miRNAs which could target this particular sequence. 
This leaves the possibility of a potential transcriptional regulation of ERK3/4 and MK5 by 
other miRNAs with possible target binding sites in other parts of the ERK3/4 and MK5 
3‟UTR or -mRNAs. 
Since we saw no change in mRNA levels of ERK3, ERK4 or MK5 in any of the HEK-293T 
cells transfected with different miRNAs in the real time qPCR experiment (see Figure 10, 
Figure 11 and Figure 12), we made an attempt to identify a possible regulation on the 
translational level. The most commonly used approach to verify a miRNA target site is by 
using a reporter gene assay where the 3′ UTR of a predicted mRNA target is linked onto a 
luciferase reporter. A change in luciferase expression will indicate whether a miRNA binds to 
the 3‟ UTR and regulate the expression of the gene at the mRNA or protein level (221).  
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To determine if any of our selected miRNAs regulated ERK3, ERK4 or MK5 at the level of 
translation, the stably transfected cell lines containing the ERK3-, ERK4- or MK5 3‟UTR 
fused to RenSP were reverse transfected with the pertaining miRNAs. Due to limited time and 
an elaborate process of ascertaining stably transfected cells containing the 3‟UTR - renilla 
luciferase constructs, we were only able to carry out one biological replicate.  
As seen in Figure 13, we saw no significant change in the relative luciferase activity in the 
transfected constructs compared to the controls for any of the miRNAs transfected in the 
HEK293Tcells expressing ERK4 3‟UTR- RenSP. The luciferase-activity was measured 48 
hours after transfection, replicating the conditions tested in the flow cytometry experiment 
(see method 2.13) to achieve comparable transfection efficiency. Results from the luciferase 
assay (see method 2.17) clearly indicated that none of the chosen miRNAs had a binding 
interaction with the part of the ERK4 3‟UTR tested. However, this does not rule out potential 
binding to other parts of ERK4 3‟UTR or -mRNA, with subsequent regulation of the protein 
expression. 
As stated in the results, section 3.4, in the experiment aiming to identify a possible 
translational miRNA regulation of ERK3, the results showed huge variations in the relative 
luciferase activity in the N.T control and a fairly low relative luciferase activity in the N.C 
miRNA control (see Figure 14). It is impossible to draw any firm conclusions from such 
results, especially when the variations affect the control-samples which all the other samples 
are related to. As a result of this, we could look at the outcome in two different ways: 1) the 
expression of miR-26a-5p, miR-425 and miR-1297 seems to cause an up-regulation of the 
luciferase expression, if related to the N.C. miRNA, or 2) the expression of miR-26b-5p and 
miR-302a-5p cause a down-regulation of the luciferase expression, if compared to the P.C. 
construct. The second option seems more likely because the relative luciferase activity of the 
cells transfected with miR-26a-5p, miR-425 and miR-1297 are comparable to that of the P.C. 
construct. This construct expresses the ERK3 3‟UTR- RenSP, without a potential miRNA-
binding site, so the luciferase activity should not be affected by miRNA-mediated regulation. 
Therefore the expression of ERK3 3‟UTR – RenSP could be interpreted as not affected by 
miR-26a-5p, miR-425 and miR-1297. At the same time it looks as though there is a potential 
binding to the ERK3 3‟UTR by miR-26b-5p and miR-302a-5p causing a subsequent down-
regulation of the luciferase expression, suggesting a regulation at the translational level by 
these two miRNAs. 
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In the experiment aiming to identify a possible translational miRNA regulation of MK5, the 
control samples also showed substantial differences in the relative luciferase activity (see 
Figure 15). In this case the N.C. miRNA seems as the right control due to the fact that its 
luciferase activity is similar to that of the P.C. construct and to the cells transfected with miR-
944 and miR-1284. Interpretation of these results suggests a potential binding of miR-517-b, 
and miR-548d-5p, miR-518-d-5p and miR-559 to the MK5 3‟UTR, and a possible subsequent 
down-regulation of the MK5 protein expression. 
Since we only had a small part of the 3‟UTR-sequence in our vector plasmid constructs, this 
might have resulted in an inaccurate accessibility for the miRNAs. We might also have 
missed other miRNA-mRNA interactions which could have participated in regulation of the 
protein expressions of ERK3/4 and MK5 by binding to the omitted 3‟UTR-sequence or other 
parts of the transcripts. It would therefore have been optimal to include the entire 3‟UTR 
sequence of the target in the experiment (221). Reporter assays can also be misleading in that 
higher concentrations of the miRNA than the physiological concentrations are being 
transfected into the cells, and may lead to an interaction that normally would not happen in 
the body. One can note rule out that ectopic overexpression in a more or less random cell line 
can be far from the physiological situation in which miRNAs work. Also, the lack of a co-
factor environment may as well lead to a non-physiological interaction. Therefore, it is 
important to further experimentally validate the putative miRNA binding sites based on their 
physical interaction in vivo (221).  
 
In an attempt to verify the results from the luciferase reporter gene assays in a biologically 
relevant context, we wanted to explore the expression of the selected miRNAs predicted to 
bind in the 3‟UTR of ERK3 and MK5 (see Table 7) in BCCLs. When comparing to the results 
from the luciferase reporter gene assays, no simple correlation is found. Of the two miRNAs 
that caused a probable down regulation of ERK3 3‟UTR – RenSP expression, only miR-26b-
5p is detected in the cell lines. Equally, of the four miRNAs that caused a probable down 
regulation of MK5 3‟UTR – RenSP expression, only miR-517-b, and miR-548d-5p are 
detected in the cell lines and in either case no clear correlation between miRNA and protein 
expression is evident.  However some interesting tendencies were discovered through this 
biologically relevant system (see Figure 16, Figure 17, Table 8 and Table 9). 
As mentioned in the results section (3.5 and Figure 16), it seems like the miRNAs expressed 
in the different BCCL can be divided into three groups: 1. those that generally are expressed 
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at a high level in all the breast cancer cell lines (BCCL) (miR-26a, miR-26b and miR-425), 2. 
miRNAs expressed, but not highly expressed, in all or most BCCL (423-5p, miR-34c-5p, 
miR-517-b, and miR-548d-5p) and 3. miRNAs that show a very low or no expression in any 
of the cell lines (miR-922, miR-124-5p, miR-302a-5p, miR-1297, miR-944, miR-1284, miR-
1305, miR-518d-5p, and miR-559). The diverse miRNA expression pattern can probably be 
explained by the fact that miRNAs are highly tissue specific with highly variable expression 
patterns in different tissues (220). 
When comparing the expression of the ERK3-protein in the different BCCL to the pertaining 
miRNA-expressions in the same cell lines we observed an inverse correlation to the miRNAs 
expressed (see Table 8). The ERK3-expression is relatively low, while three miRNAs, miR-
26a, miR-26b and miR-425, show a relatively high expression in all the BCCL. However, in 
the luciferase reporter assay (method 2.17), only miR-26b caused a potential down-regulation 
of the luciferase expression. These results may suggest a possible miRNA-mediated 
regulation of the ERK3 protein level by miR-26b in these BCCL. Still a verification of a 
potential miRNA mediated ERK3 regulation remains to be identified or confirmed 
experimentally. In the case of MK5, there was an overall low or no expression of the miRNAs 
with predicted binding sites in the MK5 3‟UTR. Interestingly, in the BCCL with the highest 
expression of MK5 (DU4475, MA11 and MCF7) almost none of the selected miRNAs were 
detected. In fact, mutual exclusive expression of miRNAs and their targets has been shown on 
a large scale by independent studies in mammals (226), and flies (227). Although a mutual 
exclusive expression of miRNAs and MK5 may exist a possible interaction between these 
miRNAs and MK5 would have to be verified experimentally. 
Studies have shown that the ERK3/4-MK5 pathway can participate in several processes that 
are deregulated in cancer, including cell proliferation and -motility, invasiveness, and 
angiogenesis. Nevertheless, even though ERK3 expression has been reported to be 
upregulated in breast cancer (228), no clear role for either of the members of the ERK3/4-
MK5 pathway in breast cancer is currently evident. The fact that the physiological role of the 
ERK3/4/ and MK5 signaling module is still enigmatic, lead us to explore a potential miRNA 
mediated regulation of these kinases. Despite the fact that a substantial part of our results are 
hampered by a limited amount of time, few biological and technical replicates and non-
conclusive results, we revealed a possible miRNA mediated regulation of ERK3 and MK5 
expression. In cancer there is a general need for elucidation of the deregulated RNA and 
protein networks and pathways in which miRNAs participate or contribute. This includes 
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miRNA target identification and verification, miRNA/phenotype associations and generation 
of network models of miRNA function. Undoubtedly, the future will bring more details, 
which will shed light on the role of the atypical kinases ERK3, ERK4 and MK5 in cancer and 
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Potential microRNA-binding sites in the 3’UTR-region of the genes MAPK4 (ERK4), 
MAPK6 (ERK3) and MAPKAPK5 (MK5). 
 
The following 3‟UTR sequences are cloned with luciferase in the constructs from Sigma, 


























Table 10. Putative microRNAs for potential binding of the 3’UTR-sequences in the 3’UTR Lenti GoClone 
of the genes MAPK4 (ERK4), MAPK6 (ERK3) and MAPKAPK5 (MK5). 
MAPK4 MAPK6 MAPKAPK5 
hsa-miR-423-5p (7 mer) 
3’UTR position: 61-89 
hsa-miR-26a (9mer) 
3’UTR position: 60-88 
 
hsa-miR-517-b (7mer) 
3’UTR position: 160-188 
 
hsa-miR-922 (9 mer) 
3’UTR position: 68-96 
 
hsa-miR-26b (9mer) 
3’UTR position: 60-88 
hsa-miR-944 (7mer) 
3’UTR position: 61-89 
 
hsa-miR-34c-5p (6 mer) 
3’ UTR position: 70-98 
 
hsa-miR-302a-5p (8mer) 
3’UTR position: 45-73 
 
hsa-miR-1284 (9mer) 
3’UTR position: 93-121 
hsa-miR-124 (6 mer) 
3’UTR position: 72-100 
hsa-miR-425 (8mer) 
3’UTR position: 75-103 
hsa-miR-1284 (6mer) 
3’UTR position: 124-152 
 
 hsa-miR-1297 (9mer) 
3’UTR position: 60-88 
 
hsa-miR-1305 (7mer) 
3’UTR position: 9-37 
 
  hsa-miR-548d-5p (8mer) 
3’UTR position: 175-203 
 
  hsa-miR-518-d (7mer) 
3’UTR position: 159-187 
 
  hsa-miR-559 (8mer) 














Table 11. Through FLOW Cytometry analysis, reverse transfection showed higher transfection efficiency 
than traditional transfection: 
Transfection 
method Sample 
Percentage (%) cells not-
fluorescent 
Percentage (%) of cells 
fluorescent 
Traditional 





























































































Figure 18. Results from the protein assay. Adjuvant concentrations (AdjConc) are given in µg/µl. Un01: 
DU4475, Un02: DU4475 sample 2, Un03: HCC1569, Un04: HCC1569 sample 2, Un05: HCC1187, Un06: 
Hs578T, Un07: AU565, Un08: MDAMB231, Un09: MCF7, Un10: MA11. Samples used for western blot 






Figure 19. Results from protein assay of MDAMB231 (Un01 and Un02), prepared in the same way as in 












           
Figure 20. Expression of actin in breast cancer cell lines. Actin-control on the blots of MK5 (see figure 1). Anti-




Figure 21. Expression of actin in breast cancer cell lines. Actin-control on the blot of ERK3 (see figure 3). Anti-





Quantification of western blots shows variations in the expressions of the proteins MK5 
and ERK3 between the different breast cancer cell lines. 
 
Table 12. Results from the western blot quantification of β-actin on MK5 (see Figure 20, left-hand blot): 










Table 13. Results from of the western blot quantification of β-actin on MK5 (see Figure 20, right-hand 
blot): 









Table 14. Results from the western blot quantification of β-actin on ERK 3 (see Figure 21): 
Sample Actin control (I.I.) 
AU565 56,71 
DU4475 100,7 
HCC1187 43,33 
HCC1569 61,97 
Hs578T 87,11 
MA11 44,43 
MCF7 89,76 
MDAMB231 51,74 
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